NCT Number,Study Title,Study URL,Study Status,Conditions,Interventions,Sponsor,Collaborators,Study Type,Completion Date
NCT00402142,Dendritic Cell Vaccine in HIV-1 Infection,https://clinicaltrials.gov/study/NCT00402142,COMPLETED,HIV Infections,BIOLOGICAL: Dendritic cell vaccine|BIOLOGICAL: non pulsed dendritic cell untreated patients|BIOLOGICAL: pulsed dendritic cell vaccine|BIOLOGICAL: dendritic cell vaccine|BIOLOGICAL: non pulsed dendritic cell vaccine,Hospital Clinic of Barcelona,,INTERVENTIONAL,2011-12
NCT06193733,Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection-phase II Clinical Trial,https://clinicaltrials.gov/study/NCT06193733,NOT_YET_RECRUITING,Hepatocellular Carcinoma,BIOLOGICAL: Autologous Dendritic Cell,Chang Gung Memorial Hospital,,INTERVENTIONAL,2028-02
NCT01676779,mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma,https://clinicaltrials.gov/study/NCT01676779,COMPLETED,Malignant Melanoma Stage III|Malignant Melanoma Stage IV,BIOLOGICAL: Dendritic cell therapy,Universitair Ziekenhuis Brussel,RIZIV,INTERVENTIONAL,2016-09
NCT01897207,Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer,https://clinicaltrials.gov/study/NCT01897207,COMPLETED,Cancer of the Prostate,BIOLOGICAL: Dendritic cell application,Cantonal Hospital of St. Gallen,,INTERVENTIONAL,2011-10
NCT00796770,Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial),https://clinicaltrials.gov/study/NCT00796770,COMPLETED,HIV,BIOLOGICAL: Dendritic Cell Vaccine,Baylor Research Institute,French National Agency for Research on AIDS and Viral Hepatitis,INTERVENTIONAL,2011-09
NCT00576537,Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors,https://clinicaltrials.gov/study/NCT00576537,COMPLETED,Glioblastoma,BIOLOGICAL: Dendritic Cell Immunotherapy,Cedars-Sinai Medical Center,,INTERVENTIONAL,2011-10
NCT03450044,Immunogenicity and Safety of DCs in Breast Cancer,https://clinicaltrials.gov/study/NCT03450044,COMPLETED,Breast Cancer Female,BIOLOGICAL: Dendritic cells,Fundación Salud de los Andes,Universidad Nacional de Colombia|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS),INTERVENTIONAL,2018-08
NCT03337165,Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis,https://clinicaltrials.gov/study/NCT03337165,COMPLETED,"Musculoskeletal Diseases|Joint Disease|Arthritis|Arthritis, Rheumatoid|Rheumatic Diseases|Connective Tissue Diseases|Autoimmune Diseases|Immune System Diseases",BIOLOGICAL: tolerogenic dendritic cells,Russian Academy of Medical Sciences,,INTERVENTIONAL,2019-08
NCT05809752,A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV),https://clinicaltrials.gov/study/NCT05809752,RECRUITING,Leptomeningeal Disease|Triple Negative Breast Cancer|HER2-positive Breast Cancer,BIOLOGICAL: Dendritic Cell Vaccine,H. Lee Moffitt Cancer Center and Research Institute,United States Department of Defense,INTERVENTIONAL,2026-03
NCT01530698,Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients,https://clinicaltrials.gov/study/NCT01530698,COMPLETED,Melanoma,BIOLOGICAL: autologous dendritic cell vaccine|BIOLOGICAL: autologous dendritic cell vaccine,Radboud University Medical Center,,INTERVENTIONAL,2014-11
NCT00445913,Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study,https://clinicaltrials.gov/study/NCT00445913,COMPLETED,Type 1 Diabetes,BIOLOGICAL: Diabetes-suppressive dendritic cell vaccine|BIOLOGICAL: control dendritic cells,University of Pittsburgh,,INTERVENTIONAL,2016-02
NCT00125749,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells,https://clinicaltrials.gov/study/NCT00125749,COMPLETED,Melanoma|Neoplasm Metastasis,BIOLOGICAL: Dendritic cell vaccination,Baylor Research Institute,Mary Crowley Medical Research Center|ODC Therapy,INTERVENTIONAL,2007-06
NCT00390338,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00390338,COMPLETED,Melanoma (Skin),BIOLOGICAL: polarized dendritic cells|BIOLOGICAL: non-polarized dendritic cells,Pawel Kalinski,National Cancer Institute (NCI),INTERVENTIONAL,2015-01
NCT00700167,Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy,https://clinicaltrials.gov/study/NCT00700167,COMPLETED,Melanoma,BIOLOGICAL: dendritic cell vaccine,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI)|National Institutes of Health (NIH)|Rockefeller University,INTERVENTIONAL,2011-04
NCT01197625,Vaccine Therapy in Curative Resected Prostate Cancer Patients,https://clinicaltrials.gov/study/NCT01197625,ACTIVE_NOT_RECRUITING,Prostate Cancer,BIOLOGICAL: Dendritic cell vaccine,Oslo University Hospital,,INTERVENTIONAL,2025-09
NCT01171729,Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer,https://clinicaltrials.gov/study/NCT01171729,COMPLETED,Prostatic Cancer,BIOLOGICAL: Autologous dendritic cell,Samsung Medical Center,"National Cancer Center, Korea",INTERVENTIONAL,2010-05
NCT05504707,DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer,https://clinicaltrials.gov/study/NCT05504707,RECRUITING,Triple Negative Breast Cancer|HER2-negative Breast Cancer,BIOLOGICAL: HER2 - primed Dendritic cells|BIOLOGICAL: HER3 - primed Dendritic cells,H. Lee Moffitt Cancer Center and Research Institute,The Shulas' Foundation,INTERVENTIONAL,2025-10
NCT01431196,Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer,https://clinicaltrials.gov/study/NCT01431196,COMPLETED,Stage II Breast Cancer|Stage III Breast Cancer,BIOLOGICAL: Autologous dendritic cell vaccination,"Clinica Universidad de Navarra, Universidad de Navarra",Spanish Clinical Research Network - SCReN|National Institutes of Health (NIH),INTERVENTIONAL,2013-12
NCT01677962,A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma,https://clinicaltrials.gov/study/NCT01677962,COMPLETED,Pancreatic Adenocarcinoma Non-resectable,BIOLOGICAL: Poly-ICLC|BIOLOGICAL: dendritic cell,Medical University of South Carolina,,INTERVENTIONAL,2016-05
NCT04552886,Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma,https://clinicaltrials.gov/study/NCT04552886,COMPLETED,Glioblastoma,BIOLOGICAL: TH-1 Dendritic Cell Immunotherapy,The Cooper Health System,Baylor College of Medicine|Philadelphia College of Osteopathic Medicine,INTERVENTIONAL,2023-12-01
NCT00576446,Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients,https://clinicaltrials.gov/study/NCT00576446,COMPLETED,Malignant Glioma,BIOLOGICAL: Dendritic cell Vaccine,Cedars-Sinai Medical Center,,INTERVENTIONAL,2012-05
NCT01006044,Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection,https://clinicaltrials.gov/study/NCT01006044,COMPLETED,Glioblastoma Multiforme,BIOLOGICAL: autologous dendritic cells,"Clinica Universidad de Navarra, Universidad de Navarra",,INTERVENTIONAL,2014-08
NCT00940004,Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients,https://clinicaltrials.gov/study/NCT00940004,COMPLETED,Melanoma,BIOLOGICAL: autologous dendritic cell vaccination,Radboud University Medical Center,,INTERVENTIONAL,2014-11
NCT01171469,Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor,https://clinicaltrials.gov/study/NCT01171469,COMPLETED,Brain Tumor|Glioblastoma|Medulloblastoma|Ependymoma|Anaplastic Astrocytoma,BIOLOGICAL: Dendritic Cells|DRUG: Imiquimod,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL,2012-06
NCT00323115,Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme,https://clinicaltrials.gov/study/NCT00323115,COMPLETED,Glioblastoma Multiforme,BIOLOGICAL: Autologous Dendritic Cell|DRUG: Temozolomide|PROCEDURE: Radiotherapy|BIOLOGICAL: Dendritic Cell Vaccine,Dartmouth-Hitchcock Medical Center,,INTERVENTIONAL,2013-07
NCT00847106,Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients,https://clinicaltrials.gov/study/NCT00847106,COMPLETED,Melanoma,DRUG: Daclizumab|BIOLOGICAL: Dendritic cells,Radboud University Medical Center,Dutch Cancer Society,INTERVENTIONAL,2005-10
NCT04879888,Personalized Vaccine for Cancer Immunotherapy,https://clinicaltrials.gov/study/NCT04879888,COMPLETED,Breast Cancer Female,BIOLOGICAL: Peptide pulsed Dendritic cell,Universidad Nacional de Colombia,Fundación Salud de los Andes|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)|Subred Integrada de Servicios de Salud Sur ESE - Colombia (South America),INTERVENTIONAL,2017-07-30
NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,https://clinicaltrials.gov/study/NCT04105582,COMPLETED,Breast Cancer|Triple Negative Breast Cancer,BIOLOGICAL: Neo-antigen pulsed Dendritic cell,Universidad Nacional de Colombia,Fundación Salud de los Andes,INTERVENTIONAL,2022-02-01
NCT04115761,Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients,https://clinicaltrials.gov/study/NCT04115761,RECRUITING,GBM,BIOLOGICAL: autologous dendritic cells,"Ever Supreme Bio Technology Co., Ltd.",,INTERVENTIONAL,2026-12-30
NCT00833781,A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects,https://clinicaltrials.gov/study/NCT00833781,COMPLETED,HIV-1 Infection|HIV Infections,BIOLOGICAL: mRNA-transfected autologous dendritic cells|BIOLOGICAL: autologous dendritic cells with no mRNA transfection,Massachusetts General Hospital,National Institute of Allergy and Infectious Diseases (NIAID),INTERVENTIONAL,2013-12
NCT01413295,Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01413295,COMPLETED,Colorectal Neoplasms,DRUG: Dendritic Cell Vaccine|OTHER: Supportive treatment,Fundacion Clinic per a la Recerca Biomédica,,INTERVENTIONAL,2014-09
NCT01734564,Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors,https://clinicaltrials.gov/study/NCT01734564,COMPLETED,Neoplasms,"BIOLOGICAL: Hiltonol and autologous dendritic cells|RADIATION: Hiltonol, dendritic cells and radiation","Clinica Universidad de Navarra, Universidad de Navarra",,INTERVENTIONAL,2016-12
NCT04590872,An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes,https://clinicaltrials.gov/study/NCT04590872,RECRUITING,Type 1 Diabetes Mellitus,BIOLOGICAL: Tolerogenic Dendritic Cell Vaccine,City of Hope Medical Center,,INTERVENTIONAL,2024-12-10
NCT03726307,Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study,https://clinicaltrials.gov/study/NCT03726307,RECRUITING,Kidney Transplant|Renal Transplant Recipients,BIOLOGICAL: DCreg: 0.5 million cells/kg+SOC|BIOLOGICAL: DCreg: 1.2 million cells/kg+SOC|BIOLOGICAL: DCreg:2.5 to 5.0 million cells/kg+SOC,National Institute of Allergy and Infectious Diseases (NIAID),University of Pittsburgh,INTERVENTIONAL,2025-07
NCT00243529,Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients,https://clinicaltrials.gov/study/NCT00243529,COMPLETED,Melanoma Stage III or IV,BIOLOGICAL: autologous dendritic cell vaccine,Radboud University Medical Center,Dutch Cancer Society,INTERVENTIONAL,
NCT03186118,Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia,https://clinicaltrials.gov/study/NCT03186118,ACTIVE_NOT_RECRUITING,CD 19+ Acute Leukemia,BIOLOGICAL: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC),Seattle Children's Hospital,,INTERVENTIONAL,2033-07
NCT00228189,Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT00228189,COMPLETED,Colorectal Cancer|Liver Metastases,BIOLOGICAL: CEA-loaded dendritic cell vaccine,Radboud University Medical Center,,INTERVENTIONAL,2010-11
NCT02107404,Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer,https://clinicaltrials.gov/study/NCT02107404,COMPLETED,Prostate Cancer,BIOLOGICAL: Dendritic Cells DCVAC/PCa,SOTIO a.s.,,INTERVENTIONAL,2017-05-22
NCT02137746,Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer,https://clinicaltrials.gov/study/NCT02137746,COMPLETED,Prostate Cancer,BIOLOGICAL: Dendritic Cells DCVAC/PCa,SOTIO a.s.,,INTERVENTIONAL,2017-03-20
NCT06435351,Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy,https://clinicaltrials.gov/study/NCT06435351,RECRUITING,Breast Cancer|Triple Negative Breast Cancer,PROCEDURE: Leukapheresis|BIOLOGICAL: Dendritic Cell (DC) Vaccine,H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL,2029-05
NCT00547144,Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer,https://clinicaltrials.gov/study/NCT00547144,COMPLETED,Pancreatic Cancer,DRUG: Gemcitabine|PROCEDURE: Dendritic Cell Immunotherapy,George Albert Fisher,,INTERVENTIONAL,2008-04
NCT00458653,Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma,https://clinicaltrials.gov/study/NCT00458653,COMPLETED,Multiple Myeloma,BIOLOGICAL: Dendritic Cell Tumor Fusion,Beth Israel Deaconess Medical Center,Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Rambam Health Care Campus,INTERVENTIONAL,2020-07
NCT00099593,Immunization Against Tumor Cells in Sezary Syndrome,https://clinicaltrials.gov/study/NCT00099593,COMPLETED,Cutaneous T-cell Lymphoma|Sezary Syndrome,BIOLOGICAL: Autologous Dendritic Cell Vaccine,University of Pittsburgh,,INTERVENTIONAL,2007-09
NCT00576641,Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma,https://clinicaltrials.gov/study/NCT00576641,COMPLETED,Brain Stem Glioma|Glioblastoma,BIOLOGICAL: autologous dendritic cells,Cedars-Sinai Medical Center,,INTERVENTIONAL,2012-04
NCT00683670,Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma,https://clinicaltrials.gov/study/NCT00683670,COMPLETED,Melanoma,DRUG: cyclophosphamide|BIOLOGICAL: Mature dendritic cell vaccine,University of Pennsylvania,,INTERVENTIONAL,2016-06
NCT01291420,Dendritic Cell Vaccination for Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT01291420,COMPLETED,Glioblastoma|Renal Cell Carcinoma|Sarcomas|Breast Cancers|Malignant Mesothelioma|Colorectal Tumors,BIOLOGICAL: autologous dendritic cell vaccination,"University Hospital, Antwerp",,INTERVENTIONAL,2018-05-05
NCT06195618,Personalized Vaccine for TNBC Immunotherapy,https://clinicaltrials.gov/study/NCT06195618,NOT_YET_RECRUITING,Breast Cancer Female,BIOLOGICAL: Peptide pulsed autologous Dendritic cell,Universidad Nacional de Colombia,Fundación Salud de los Andes,INTERVENTIONAL,2026-06-01
NCT02649829,Autologous Dendritic Cell Vaccination in Mesothelioma,https://clinicaltrials.gov/study/NCT02649829,ACTIVE_NOT_RECRUITING,Malignant Pleural Mesothelioma,BIOLOGICAL: dendritic cell vaccination plus chemotherapy,"University Hospital, Antwerp",Kom Op Tegen Kanker|Stichting tegen Kanker,INTERVENTIONAL,2025-03
NCT00012064,Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma,https://clinicaltrials.gov/study/NCT00012064,COMPLETED,Melanoma (Skin),BIOLOGICAL: therapeutic autologous dendritic cells,"Lisata Therapeutics, Inc.",,INTERVENTIONAL,2011-04
NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,https://clinicaltrials.gov/study/NCT00243594,COMPLETED,Melanoma Stage III or IV,BIOLOGICAL: Peptide-pulsed dendritic cells,Radboud University Medical Center,Dutch Cancer Society,INTERVENTIONAL,
NCT01826877,Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer,https://clinicaltrials.gov/study/NCT01826877,COMPLETED,Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer,BIOLOGICAL: AdGMCAIX-transduced autologous dendritic cells|BIOLOGICAL: therapeutic autologous dendritic cells|OTHER: laboratory biomarker analysis,Jonsson Comprehensive Cancer Center,"Kite, A Gilead Company",INTERVENTIONAL,2021-05-27
NCT01278914,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer,https://clinicaltrials.gov/study/NCT01278914,COMPLETED,Prostate Cancer,BIOLOGICAL: Dendritic Cells (DC) prostate,Oslo University Hospital,,INTERVENTIONAL,2006-07
NCT04911621,Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma,https://clinicaltrials.gov/study/NCT04911621,ACTIVE_NOT_RECRUITING,High Grade Glioma|Diffuse Intrinsic Pontine Glioma,BIOLOGICAL: Dendritic cell vaccination + temozolomide-based chemoradiation|BIOLOGICAL: Dendritic cell vaccination +- conventional next-line treatment,"University Hospital, Antwerp",Kom Op Tegen Kanker|Stichting Semmy|Olivia Hendrickx research Fund vzw,INTERVENTIONAL,2027-06-01
NCT03291444,CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS,https://clinicaltrials.gov/study/NCT03291444,RECRUITING,"Leukemia, Acute Lymphocytic (ALL)|Leukemia, Acute Myelogenous (AML)|Myelodysplastic Syndromes",BIOLOGICAL: Chimeric antigen receptor T cells|BIOLOGICAL: peptide specific dendritic cell,Zhujiang Hospital,Shenzhen Geno-Immune Medical Institute|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,INTERVENTIONAL,2025-06-01
NCT01446731,Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer,https://clinicaltrials.gov/study/NCT01446731,COMPLETED,Prostatic Neoplasms,BIOLOGICAL: mRNA transfected dendritic cell|DRUG: Docetaxel,Inge Marie Svane,,INTERVENTIONAL,2015-08
NCT02063724,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer,https://clinicaltrials.gov/study/NCT02063724,COMPLETED,Breast Cancer,BIOLOGICAL: HER-2 pulsed Dendritic Cell Vaccine,H. Lee Moffitt Cancer Center and Research Institute,Abramson Cancer Center at Penn Medicine,INTERVENTIONAL,2022-09
NCT06524063,Targeted Survivin DC Cell Injection for the Treatment of GBM,https://clinicaltrials.gov/study/NCT06524063,NOT_YET_RECRUITING,Glioblastoma,DRUG: Survivin-loaded dendritic cell injection,Beijing Tricision Biotherapeutics Inc,,INTERVENTIONAL,2027-10-01
NCT04912765,Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC,https://clinicaltrials.gov/study/NCT04912765,RECRUITING,Hepatocellular Carcinoma|Hepatocellular Cancer|Colorectal Cancer|Colorectal Carcinoma|Liver Metastases,BIOLOGICAL: Neoantigen Dendritic Cell Vaccine|DRUG: Nivolumab,"National Cancer Centre, Singapore",Bristol-Myers Squibb,INTERVENTIONAL,2025-05
NCT00103116,"Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00103116,COMPLETED,Lung Cancer,BIOLOGICAL: autologous dendritic cell cancer vaccine,Edward Hirschowitz,National Cancer Institute (NCI),INTERVENTIONAL,2008-04
NCT05773859,NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer,https://clinicaltrials.gov/study/NCT05773859,RECRUITING,Epithelial Ovarian Cancer|Ovarian Carcinoma,BIOLOGICAL: XP-DC vaccinations,Radboud University Medical Center,,INTERVENTIONAL,2025-10
NCT04523688,Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate in Glioblastoma,https://clinicaltrials.gov/study/NCT04523688,RECRUITING,Glioblastoma|Vaccination,BIOLOGICAL: Autologous Dendritic Cells (DC) vaccine|DRUG: Temozolomide,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,INTERVENTIONAL,2025-12
NCT00856154,Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection,https://clinicaltrials.gov/study/NCT00856154,COMPLETED,HIV Infections,BIOLOGICAL: Peptides on autologous Dendritic Cells,Statens Serum Institut,"Hvidovre University Hospital|Rigshospitalet, Denmark",INTERVENTIONAL,2008-10
NCT02061423,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy,https://clinicaltrials.gov/study/NCT02061423,COMPLETED,Breast Cancer,BIOLOGICAL: HER-2 pulsed Dendritic Cell Vaccine,H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL,2024-02-21
NCT00937183,Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma,https://clinicaltrials.gov/study/NCT00937183,COMPLETED,Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,BIOLOGICAL: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|BIOLOGICAL: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|BIOLOGICAL: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine,Jan Walewski,,INTERVENTIONAL,2017-12
NCT03548571,Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy,https://clinicaltrials.gov/study/NCT03548571,RECRUITING,Glioblastoma,BIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide,Oslo University Hospital,,INTERVENTIONAL,2026-05-01
NCT01067287,Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT01067287,ACTIVE_NOT_RECRUITING,Multiple Myeloma,DRUG: CT-011|BIOLOGICAL: Dendritic Cell Fusion Vaccine,Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute|Brigham and Women's Hospital|Rambam Health Care Campus|Gateway for Cancer Research|United States Department of Defense,INTERVENTIONAL,2024-12
NCT00162929,Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe),https://clinicaltrials.gov/study/NCT00162929,COMPLETED,Metastatic Breast Cancer,BIOLOGICAL: AdHer-2/neu transduced dendritic cells,Ontario Clinical Oncology Group (OCOG),Ontario Cancer Research Network|Canadian Breast Cancer Research Alliance,INTERVENTIONAL,2012-05
NCT02649582,Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients,https://clinicaltrials.gov/study/NCT02649582,ACTIVE_NOT_RECRUITING,Glioblastoma Multiforme of Brain,BIOLOGICAL: Dendritic cell vaccine plus temozolomide chemotherapy,"University Hospital, Antwerp",,INTERVENTIONAL,2025-12
NCT02820584,A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma,https://clinicaltrials.gov/study/NCT02820584,COMPLETED,de Novo Glioblastoma,BIOLOGICAL: GSC-loaded autologous dendritic cells,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,INTERVENTIONAL,2017-06
NCT00006434,Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00006434,COMPLETED,"Lymphoma, Non-Hodgkin",BIOLOGICAL: tumor-pulsed dendritic cells,National Center for Research Resources (NCRR),,INTERVENTIONAL,
NCT06522919,Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06522919,NOT_YET_RECRUITING,Colorectal Cancer Metastatic|Microsatellite Stable Colorectal Carcinoma|Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer,BIOLOGICAL: Autologous Dendritic Cell (DC) Vaccine,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,INTERVENTIONAL,2026-09-01
NCT02061332,DC Vaccine for Patients With Ductal Carcinoma In Situ,https://clinicaltrials.gov/study/NCT02061332,COMPLETED,Breast Cancer|DCIS,BIOLOGICAL: HER-2 Pulsed Dendritic cell Vaccine,Abramson Cancer Center at Penn Medicine,,INTERVENTIONAL,2015-10-07
NCT03152565,Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT03152565,COMPLETED,Colorectal Carcinoma,DRUG: Avelumab,Grupo Espanol Multidisciplinario del Cancer Digestivo,,INTERVENTIONAL,2020-10-05
NCT05767684,Neoantigen Derived DCs as Cancer Treatment,https://clinicaltrials.gov/study/NCT05767684,RECRUITING,Refractory Tumor|Solid Tumor,BIOLOGICAL: Dendritic Cell Vaccine|DRUG: Lenvatinib|DRUG: Nivolumab,"National Health Research Institutes, Taiwan",National Cheng-Kung University Hospital,INTERVENTIONAL,2026-03-30
NCT01617629,Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study,https://clinicaltrials.gov/study/NCT01617629,COMPLETED,Epithelial Ovarian Cancer,BIOLOGICAL: MUC1 Dendritic Cell Vaccine (Cvac),Prima BioMed Ltd,,INTERVENTIONAL,2014-04
NCT00108264,Tumor RNA Transfected Dendritic Cell Vaccines,https://clinicaltrials.gov/study/NCT00108264,COMPLETED,Prostate Cancer,BIOLOGICAL: Tumor RNA transfected dendritic cells,US Department of Veterans Affairs,,INTERVENTIONAL,2005-09
NCT03546426,Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies,https://clinicaltrials.gov/study/NCT03546426,ACTIVE_NOT_RECRUITING,"Mesothelioma, Malignant|PD-L1 Negative|Advanced Cancer|Progressive Disease",DRUG: Pembrolizumab|BIOLOGICAL: Autologous dendritic cells|DRUG: Interleukin-2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,INTERVENTIONAL,2028-09
NCT00893945,Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors,https://clinicaltrials.gov/study/NCT00893945,COMPLETED,Brain Tumors,DRUG: DC/AAT|DRUG: DC/AAT-Flu|DRUG: DC/KLH,Rockefeller University,Memorial Sloan Kettering Cancer Center,INTERVENTIONAL,2013-12
NCT03114631,Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer,https://clinicaltrials.gov/study/NCT03114631,COMPLETED,Dendritic Cells|Pancreatic Neoplasms,BIOLOGICAL: Dendritic cells pulsed with tumor lysate|BIOLOGICAL: Dendritic cells pulsed with MUC-1/WT-1 peptides,The Republican Research and Practical Center for Epidemiology and Microbiology,Belarusian State Medical University,INTERVENTIONAL,2019-05-23
NCT02105675,Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT02105675,COMPLETED,Prostate Cancer|Prostate Cancer Metastatic,BIOLOGICAL: Dendritic Cells DCVAC/PCa|DRUG: Docetaxel,SOTIO a.s.,,INTERVENTIONAL,2017-02-20
NCT00345293,Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer,https://clinicaltrials.gov/study/NCT00345293,COMPLETED,Prostate Cancer,BIOLOGICAL: autologous dendritic cell vaccine (DC/PC3),Rockefeller University,Memorial Sloan Kettering Cancer Center,INTERVENTIONAL,2015-03
NCT00963521,Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission,https://clinicaltrials.gov/study/NCT00963521,COMPLETED,Leukemia,BIOLOGICAL: therapeutic autologous dendritic cells,Institut Paoli-Calmettes,,INTERVENTIONAL,
NCT00068510,Vaccine Therapy in Treating Patients With Malignant Glioma,https://clinicaltrials.gov/study/NCT00068510,COMPLETED,Brain and Central Nervous System Tumors,BIOLOGICAL: therapeutic autologous dendritic cells,Jonsson Comprehensive Cancer Center,National Institutes of Health (NIH),INTERVENTIONAL,2012-09
NCT00272649,Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer,https://clinicaltrials.gov/study/NCT00272649,COMPLETED,Renal Cell Carcinoma,BIOLOGICAL: AGS-003,Argos Therapeutics,,INTERVENTIONAL,2012-02
NCT00039325,Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma,https://clinicaltrials.gov/study/NCT00039325,COMPLETED,Melanoma (Skin),BIOLOGICAL: dendritic cell-MART-1 peptide vaccine,Jonsson Comprehensive Cancer Center,National Institutes of Health (NIH),INTERVENTIONAL,2009-06
NCT03164265,DCreg in Living Donor Liver Transplantation,https://clinicaltrials.gov/study/NCT03164265,COMPLETED,Living Donor Liver Transplantation,BIOLOGICAL: Regulatory Donor-Derived Dendritic Cell infusion,Angus W. Thomson PhD DSc,University of Pittsburgh,INTERVENTIONAL,2024-07-15
NCT00107185,Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma,https://clinicaltrials.gov/study/NCT00107185,COMPLETED,Brain and Central Nervous System Tumors,BIOLOGICAL: therapeutic autologous dendritic cells,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,2010-03
NCT00459069,The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma,https://clinicaltrials.gov/study/NCT00459069,COMPLETED,Multiple Myeloma,BIOLOGICAL: Dendritic Cell Tumor Fusion Vaccine,Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute|Brigham and Women's Hospital,INTERVENTIONAL,2009-11
NCT00798629,Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured,https://clinicaltrials.gov/study/NCT00798629,COMPLETED,Melanoma (Skin),BIOLOGICAL: Autologous dendritic cell-adenovirus CCL21 vaccine,H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI),INTERVENTIONAL,2012-04
NCT04212377,Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients,https://clinicaltrials.gov/study/NCT04212377,COMPLETED,Endometrial Cancer,BIOLOGICAL: Dendritic Cells for endometrial cancer,Radboud University Medical Center,Stichting Katholieke Universiteit,INTERVENTIONAL,2021-03-09
NCT05378464,Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,https://clinicaltrials.gov/study/NCT05378464,RECRUITING,HER2-positive Breast Cancer,BIOLOGICAL: Dendritic Cell (DC1) Vaccine|DRUG: Trastuzumab|DRUG: Pepinemab|BIOLOGICAL: T-Cell therapy,H. Lee Moffitt Cancer Center and Research Institute,Vaccinex Inc.,INTERVENTIONAL,2026-12
NCT02423928,Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer,https://clinicaltrials.gov/study/NCT02423928,COMPLETED,Prostate Cancer,BIOLOGICAL: Dendritic cell based cryoimmunotherapy|DRUG: Cyclophosphamide|DRUG: ipilimumab,Alden Cancer Therapy II,Haukeland University Hospital|Norwegian Radium Hospital,INTERVENTIONAL,2019-08-16
NCT00056758,HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs,https://clinicaltrials.gov/study/NCT00056758,COMPLETED,HIV Infections,BIOLOGICAL: Autologous Dendritic Cell HIV Vaccination,National Institute of Allergy and Infectious Diseases (NIAID),,INTERVENTIONAL,
NCT01456104,Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma,https://clinicaltrials.gov/study/NCT01456104,COMPLETED,Melanoma,BIOLOGICAL: Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs),Memorial Sloan Kettering Cancer Center,Rockefeller University,INTERVENTIONAL,2023-01-12
NCT04348747,Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer,https://clinicaltrials.gov/study/NCT04348747,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,BIOLOGICAL: Anti-HER2/HER3 Dendritic Cell Vaccine|BIOLOGICAL: Pembrolizumab,Roswell Park Cancer Institute,United States Department of Defense,INTERVENTIONAL,2026-12-15
NCT00197912,Dendritic Cell Based Therapy of Malignant Melanoma,https://clinicaltrials.gov/study/NCT00197912,COMPLETED,Advanced Melanoma,BIOLOGICAL: tumor antigen loaded autologous dendritic cells,Herlev Hospital,,INTERVENTIONAL,2010-04
NCT00186316,Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells,https://clinicaltrials.gov/study/NCT00186316,COMPLETED,Multiple Myeloma,BIOLOGICAL: Idiotype-pulsed allogeneic dendritic cells,Stanford University,National Cancer Institute (NCI),INTERVENTIONAL,2008-12
NCT00948480,Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells,https://clinicaltrials.gov/study/NCT00948480,COMPLETED,Metastatic Melanoma,BIOLOGICAL: Autologous tumor cells plus dendritic cells|DRUG: GM-CSF,Hoag Memorial Hospital Presbyterian,,INTERVENTIONAL,2007-09
NCT00601094,"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00601094,COMPLETED,Lung Cancer,BIOLOGICAL: autologous dendritic cell-adenovirus CCL21 vaccine,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,2017-05-23
NCT01808820,Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma,https://clinicaltrials.gov/study/NCT01808820,COMPLETED,Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|High Grade Glioma,BIOLOGICAL: Dendritic Cell Vaccine|BIOLOGICAL: Tumor Lysate|DRUG: Imiquimod|PROCEDURE: Leukapheresis,"Macarena De La Fuente, MD",,INTERVENTIONAL,2022-07-16
NCT00988312,Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma,https://clinicaltrials.gov/study/NCT00988312,COMPLETED,Multiple Myeloma|Plasmocytoma,BIOLOGICAL: autologous idiotype-protein pulsed dendritic cells,University Hospital Carl Gustav Carus,,INTERVENTIONAL,2004-03
NCT03395587,Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma,https://clinicaltrials.gov/study/NCT03395587,RECRUITING,Glioblastoma,"BIOLOGICAL: Autologous, tumor lysate-loaded, mature dendritic cells (DC)|DRUG: standard therapy","Heinrich-Heine University, Duesseldorf",German Federal Ministry of Education and Research,INTERVENTIONAL,2027-03-06
NCT04184232,Treatment of Recurrent Bladder Cancer With Dendritic Cells,https://clinicaltrials.gov/study/NCT04184232,COMPLETED,Bladder Cancer,BIOLOGICAL: Dendritic cells|OTHER: Standard treatment according to the Clinical protocols,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Belarusian State Medical University,INTERVENTIONAL,2020-12-31
NCT00197860,Dendritic Cell Based Therapy of Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00197860,COMPLETED,Advanced Renal Cell Carcinoma,BIOLOGICAL: tumor antigen loaded autologous dendritic cells,Inge Marie Svane,,INTERVENTIONAL,2010-10
NCT06253234,Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas,https://clinicaltrials.gov/study/NCT06253234,RECRUITING,WHO Grade III Gliomas|WHO Grade IV Gliomas,BIOLOGICAL: personalized dendritic cell injection ZSNeo-DC1.1,Beijing Tiantan Hospital,ZhongSheng BioTech Inc.,INTERVENTIONAL,2025-02-04
NCT01278940,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT01278940,COMPLETED,Malignant Melanoma,BIOLOGICAL: Dendritic Cells (DC) malignant melanoma|PROCEDURE: IL-2,Oslo University Hospital,,INTERVENTIONAL,2015-12
NCT02107430,Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer,https://clinicaltrials.gov/study/NCT02107430,COMPLETED,Prostate Cancer,BIOLOGICAL: Dendritic Cells DCVAC/PCa|RADIATION: Standard radiotherapy,SOTIO a.s.,,INTERVENTIONAL,2018-10
NCT00280982,Dendritic Cell-based Immunotherapy in Mesothelioma,https://clinicaltrials.gov/study/NCT00280982,COMPLETED,Malignant Pleural Mesothelioma,BIOLOGICAL: tumor lysate-loaded autologous dendritic cells,Erasmus Medical Center,,INTERVENTIONAL,2009-09
NCT00056134,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00056134,COMPLETED,Melanoma (Skin),BIOLOGICAL: Dendritic cell vaccine plus denileukin difitox,University Hospital Erlangen,,INTERVENTIONAL,2012-05
NCT00082641,"Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer",https://clinicaltrials.gov/study/NCT00082641,COMPLETED,Breast Cancer,BIOLOGICAL: autologous dendritic cell-adenovirus p53 vaccine,University of Nebraska,National Cancer Institute (NCI)|H. Lee Moffitt Cancer Center and Research Institute,INTERVENTIONAL,2018-01-01
NCT00004211,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer,https://clinicaltrials.gov/study/NCT00004211,COMPLETED,Prostate Cancer,BIOLOGICAL: PSA RNA-pulsed dendritic cell vaccine,Duke University,National Cancer Institute (NCI),INTERVENTIONAL,2002-01
NCT01241162,Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,https://clinicaltrials.gov/study/NCT01241162,COMPLETED,Neuroblastoma|Ewings Sarcoma|Osteogenic Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma,BIOLOGICAL: Autologous dendritic cell vaccine with adjuvant,University of Louisville,Solving Kids' Cancer,INTERVENTIONAL,2016-10
NCT00004880,Vaccine Therapy in Treating Patients With Advanced Kidney Cancer,https://clinicaltrials.gov/study/NCT00004880,COMPLETED,Kidney Cancer,BIOLOGICAL: dendritic cell vaccine therapy|PROCEDURE: conventional surgery,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,
NCT05964361,First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients,https://clinicaltrials.gov/study/NCT05964361,RECRUITING,Esophageal Cancer|Pancreas Cancer|Ovarian Cancer|Liver Cancer,BIOLOGICAL: IL15-transpresenting WT1-targeted Dendritic Cell Vaccine,"University Hospital, Antwerp",Kom Op Tegen Kanker|Stichting tegen Kanker,INTERVENTIONAL,2025-09-01
NCT03546361,CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03546361,ACTIVE_NOT_RECRUITING,Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,BIOLOGICAL: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine|BIOLOGICAL: Pembrolizumab,Jonsson Comprehensive Cancer Center,California Institute for Regenerative Medicine (CIRM)|Merck Sharp & Dohme LLC|LUNGevity Foundation|National Cancer Institute (NCI),INTERVENTIONAL,2025-01-11
NCT02283671,Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B,https://clinicaltrials.gov/study/NCT02283671,COMPLETED,Multiple Sclerosis|Neuromyelitis Optica,BIOLOGICAL: Tolerogenic Dendritic cells loaded with myelin peptides,Sara Varea,,INTERVENTIONAL,2019-07-10
NCT00107159,Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00107159,COMPLETED,Melanoma (Skin),BIOLOGICAL: autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,2010-09
NCT00834002,Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission,https://clinicaltrials.gov/study/NCT00834002,COMPLETED,Acute Myeloid Leukemia (AML),BIOLOGICAL: injection of antigen-loaded cultured dendritic cells,"University Hospital, Antwerp",,INTERVENTIONAL,2008-12
NCT01946373,T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma,https://clinicaltrials.gov/study/NCT01946373,RECRUITING,Melanoma,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: T cells|BIOLOGICAL: Interleukin-2|BIOLOGICAL: Dendritic cell vaccine,Karolinska University Hospital,,INTERVENTIONAL,2025-12
NCT01410968,"A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma",https://clinicaltrials.gov/study/NCT01410968,COMPLETED,Metastatic Pancreatic Cancer,DRUG: vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells,Carolyn Britten,"Oncovir, Inc.",INTERVENTIONAL,2015-05
NCT00626483,Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia,https://clinicaltrials.gov/study/NCT00626483,COMPLETED,Malignant Neoplasms Brain,BIOLOGICAL: RNA-loaded dendritic cell vaccine|DRUG: basiliximab,Gary Archer Ph.D.,National Cancer Institute (NCI),INTERVENTIONAL,2016-07-06
NCT00852007,A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1,https://clinicaltrials.gov/study/NCT00852007,COMPLETED,Prostate Cancer,BIOLOGICAL: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1,Hamilton Health Sciences Corporation,McMaster University,INTERVENTIONAL,2016-02
NCT00970203,Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer,https://clinicaltrials.gov/study/NCT00970203,COMPLETED,"Cancer of Prostate|Cancer of the Prostate|Neoplasms, Prostate|Neoplasms, Prostatic|Prostate Cancer|Prostate Neoplasms|Prostatic Cancer",BIOLOGICAL: androgen ablation (AA)|BIOLOGICAL: DC1 vaccine,Roswell Park Cancer Institute,University of Pittsburgh,INTERVENTIONAL,2019-10-05
NCT00005617,Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma,https://clinicaltrials.gov/study/NCT00005617,COMPLETED,Melanoma,BIOLOGICAL: dendritic cell-MART-1 peptide vaccine|PROCEDURE: leukapheresis,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,
NCT03387553,HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer,https://clinicaltrials.gov/study/NCT03387553,ACTIVE_NOT_RECRUITING,"Breast Cancer|Breast Cancer Female|Breast Cancer, Male|Invasive Breast Cancer|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma|Stage II Breast Cancer|Stage III Breast Cancer",BIOLOGICAL: Dendritic Cell Vaccine (DC1)|DRUG: Neoadjuvant Chemotherapy|PROCEDURE: Curative Surgery,H. Lee Moffitt Cancer Center and Research Institute,United States Department of Defense,INTERVENTIONAL,2026-08-29
NCT04487756,Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer,https://clinicaltrials.gov/study/NCT04487756,ACTIVE_NOT_RECRUITING,Extensive-stage Small Cell Lung Cancer,DRUG: Atezolizumab 1200 mg in 20 ML Injection|BIOLOGICAL: ADC Vaccine|DRUG: Carboplatin,Instituto Oncológico Dr Rosell,Roche Pharma AG|Fundacion Clinic per a la Recerca Biomédica,INTERVENTIONAL,2024-10
NCT00058734,Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients,https://clinicaltrials.gov/study/NCT00058734,COMPLETED,HIV Infections,BIOLOGICAL: Dendritic Cells Pulsed with HIV antigens,National Institute of Allergy and Infectious Diseases (NIAID),,INTERVENTIONAL,
NCT04078269,MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04078269,ACTIVE_NOT_RECRUITING,Non-small Cell Lung Cancer,BIOLOGICAL: Dendritic cell immunotherapy|BIOLOGICAL: Antigen-specific DTH|BIOLOGICAL: Control DTH,"University Hospital, Ghent",University Ghent|Kom Op Tegen Kanker,INTERVENTIONAL,2025-12-31
NCT00005816,Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer,https://clinicaltrials.gov/study/NCT00005816,COMPLETED,Kidney Cancer,BIOLOGICAL: therapeutic autologous dendritic cells|PROCEDURE: conventional surgery,Duke University,National Cancer Institute (NCI),INTERVENTIONAL,2002-08
NCT00972309,A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer,https://clinicaltrials.gov/study/NCT00972309,COMPLETED,Prostate Specific Antigens|Prostate Neoplasms,BIOLOGICAL: T-cell receptor alternate reading frame protein (TARP) peptide vaccine|BIOLOGICAL: T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine,National Cancer Institute (NCI),,INTERVENTIONAL,2015-02-04
NCT01525017,"A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer",https://clinicaltrials.gov/study/NCT01525017,COMPLETED,Metastatic Renal Cell Carcinoma,BIOLOGICAL: Combig-DC (allogeneic dendritic cells) Cancer Vaccine,Mendus,,INTERVENTIONAL,2013-12
NCT00799110,Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod,https://clinicaltrials.gov/study/NCT00799110,ACTIVE_NOT_RECRUITING,Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer,DRUG: GM-CSF|BIOLOGICAL: Dendritic Cell/Tumor Fusion Vaccine|DRUG: imiquimod,Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|National Cancer Institute (NCI),INTERVENTIONAL,2024-12
NCT02766049,Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus,https://clinicaltrials.gov/study/NCT02766049,COMPLETED,HIV Infection,BIOLOGICAL: DC|BIOLOGICAL: DC10e6+HIV-AT2|BIOLOGICAL: DC10e7+HIV-AT2,University of Sao Paulo General Hospital,,INTERVENTIONAL,2014-05
NCT00846456,Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma,https://clinicaltrials.gov/study/NCT00846456,COMPLETED,Glioblastoma|Brain Tumor,BIOLOGICAL: Dendritic cell vaccine with mRNA from tumor stem cells,Oslo University Hospital,,INTERVENTIONAL,2013-02
NCT00019890,Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00019890,COMPLETED,Stage IV Melanoma|Stage III Melanoma|Recurrent Melanoma,DRUG: dendritic cell-gp100-MART-1 antigen vaccine|DRUG: sargramostim,National Cancer Institute (NCI),,INTERVENTIONAL,2007-03
NCT00266110,"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",https://clinicaltrials.gov/study/NCT00266110,COMPLETED,Breast Cancer,BIOLOGICAL: sargramostim|BIOLOGICAL: therapeutic autologous dendritic cells|BIOLOGICAL: trastuzumab|DRUG: vinorelbine ditartrate,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation,INTERVENTIONAL,2017-10-27
NCT04789252,Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04789252,RECRUITING,Non-small Cell Lung Cancer,BIOLOGICAL: Bioinformatics analysis of single cell transcriptomics data,University of Milano Bicocca,,OBSERVATIONAL,2026-02-09
NCT01347034,Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS),https://clinicaltrials.gov/study/NCT01347034,COMPLETED,Soft Tissue Sarcoma,PROCEDURE: External Beam Radiation Therapy (RT)|BIOLOGICAL: Autologous Dendritic Cells,H. Lee Moffitt Cancer Center and Research Institute,University of Florida,INTERVENTIONAL,2016-04
NCT03325101,Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery,https://clinicaltrials.gov/study/NCT03325101,COMPLETED,Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7,PROCEDURE: Cryosurgery|BIOLOGICAL: Pembrolizumab|PROCEDURE: Pheresis|BIOLOGICAL: Therapeutic Autologous Dendritic Cells,Mayo Clinic,,INTERVENTIONAL,2020-06-14
NCT00049218,Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00049218,COMPLETED,Lung Cancer,BIOLOGICAL: Autologous dendritic cell-adenovirus p53 vaccine|DRUG: Carboplatin|DRUG: Etoposide,H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL,2014-05
NCT01792505,Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma,https://clinicaltrials.gov/study/NCT01792505,COMPLETED,Malignant Glioma,BIOLOGICAL: Dendritic Cell Vaccine in combination with Imiquimod cream,Cedars-Sinai Medical Center,,INTERVENTIONAL,2016-10
NCT04201873,Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma,https://clinicaltrials.gov/study/NCT04201873,RECRUITING,Recurrent Glioblastoma,BIOLOGICAL: Dendritic Cell Tumor Cell Lysate Vaccine|BIOLOGICAL: Pembrolizumab|OTHER: Placebo Administration|DRUG: Poly ICLC,Jonsson Comprehensive Cancer Center,"National Cancer Institute (NCI)|Merck Sharp & Dohme LLC|Phase One Foundation|Oncovir, Inc.",INTERVENTIONAL,2026-08-01
NCT00405327,A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00405327,COMPLETED,Sarcoma|Neuroblastoma|Wilm's Tumor,BIOLOGICAL: Tumor lysate-pulsed dendritic cell (DC) vaccine|OTHER: Hematopoietic stem cell transplantation (HSCT),University of Michigan Rogel Cancer Center,,INTERVENTIONAL,2010-06
NCT05251870,Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis,https://clinicaltrials.gov/study/NCT05251870,RECRUITING,Rheumatoid Arthritis,DRUG: autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70,UMC Utrecht,Radboud University Medical Center|Utrecht University|Trajectum Pharma B.V.|Dutch Arthritis Association|ZonMw: The Netherlands Organisation for Health Research and Development|Health Holland,INTERVENTIONAL,2025-08
NCT00124124,Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine,https://clinicaltrials.gov/study/NCT00124124,COMPLETED,Melanoma,"DRUG: KLH; Peptides; Dendritic Cells|DRUG: KLH, peptides plus Montanide",Dr. Nina Bhardwaj,"Cancer Research Institute, New York City",INTERVENTIONAL,2009-04
NCT00313235,Combined Modality Treatment for Patients With Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00313235,COMPLETED,Malignant Melanoma Stage IV,BIOLOGICAL: DC Vaccine and Cyclophosphamide,Baylor Research Institute,,INTERVENTIONAL,2012-06
NCT00085488,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00085488,COMPLETED,Melanoma (Skin),BIOLOGICAL: autologous tumor cell vaccine|BIOLOGICAL: therapeutic autologous dendritic cells,Dartmouth-Hitchcock Medical Center,National Cancer Institute (NCI),INTERVENTIONAL,2006-02
NCT02728102,Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401),https://clinicaltrials.gov/study/NCT02728102,COMPLETED,Multiple Myeloma,PROCEDURE: Tumor Cell Collection|PROCEDURE: Autologous Stem Cell Transplant|DRUG: Melphalan|PROCEDURE: Leukapheresis|BIOLOGICAL: Myeloma vaccine|DRUG: GM-CSF|DRUG: Lenalidomide,"National Heart, Lung, and Blood Institute (NHLBI)",Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program,INTERVENTIONAL,2022-12-09
NCT01795573,Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease,https://clinicaltrials.gov/study/NCT01795573,COMPLETED,Graft Versus Host Disease,BIOLOGICAL: Cultured Treg cells,H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL,2020-08-14
NCT00442754,Dendritic Cells in Lung Cancer,https://clinicaltrials.gov/study/NCT00442754,COMPLETED,Non Small Cell Lung Cancer,BIOLOGICAL: Allogeneic Tumour Lysate (MelCancerVac),Herlev Hospital,University of Copenhagen,INTERVENTIONAL,2009-11
NCT03610360,DENdritic Cell Immunotherapy for Mesothelioma,https://clinicaltrials.gov/study/NCT03610360,COMPLETED,Mesothelioma,DRUG: MesoPher,Amphera BV,TMC Pharma,INTERVENTIONAL,2022-06-30
NCT02919644,Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.,https://clinicaltrials.gov/study/NCT02919644,RECRUITING,Stage IV Colorectal Cancer|Curative Resection,BIOLOGICAL: autologous dendritic cells loaded with autologous tumour homogenate|DRUG: IL2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,INTERVENTIONAL,2031-12
NCT00910650,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT00910650,COMPLETED,Metastatic Melanoma,BIOLOGICAL: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|DRUG: non-myeloablative conditioning chemotherapy,Jonsson Comprehensive Cancer Center,California Institute of Technology|University of Southern California|University of Connecticut|National Cancer Institute (NCI),INTERVENTIONAL,2019-05-30
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,https://clinicaltrials.gov/study/NCT00978913,COMPLETED,Breast Cancer|Malignant Melanoma,BIOLOGICAL: DC vaccine,Inge Marie Svane,,INTERVENTIONAL,2014-05
NCT02677155,Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma,https://clinicaltrials.gov/study/NCT02677155,COMPLETED,Follicular Lymphoma,RADIATION: Radiotherapy|BIOLOGICAL: Rituximab|BIOLOGICAL: Autologous dendritic cells|BIOLOGICAL: GM-CSF|BIOLOGICAL: Pembrolizumab,Oslo University Hospital,Norwegian Cancer Society|Merck Sharp & Dohme LLC,INTERVENTIONAL,2021-02
NCT05765084,Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT05765084,RECRUITING,Malignant Pleural Mesothelioma,BIOLOGICAL: Dendritic cell vaccination|DRUG: Atezolizumab|DRUG: Platinum/pemetrexed based chemotherapy,"University Hospital, Antwerp",Algemeen Ziekenhuis Maria Middelares|Vitaz|Kom Op Tegen Kanker|Roche Pharma AG,INTERVENTIONAL,2026-10
NCT01803152,Dendritic Cell Vaccine for Children and Adults With Sarcoma,https://clinicaltrials.gov/study/NCT01803152,COMPLETED,Sarcoma|Soft Tissue Sarcoma|Bone Sarcoma,BIOLOGICAL: Dendritic Cells Vaccine|BIOLOGICAL: Lysate of Tumor|DRUG: Gemcitabine|DRUG: Imiquimod|PROCEDURE: Leukapheresis,"Macarena De La Fuente, MD",,INTERVENTIONAL,2024-06-21
NCT00313508,Dendritic Cell Vaccination During Lymphoid Reconstruction,https://clinicaltrials.gov/study/NCT00313508,COMPLETED,Intraocular Melanoma|Melanoma (Skin),BIOLOGICAL: Autologous Dendritic Cells (DC)|DRUG: Fludarabine|BIOLOGICAL: Autologous Lymphocyte Infusion (ALI),H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI),INTERVENTIONAL,2012-03
NCT00672542,Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells,https://clinicaltrials.gov/study/NCT00672542,COMPLETED,Metastatic Melanoma|Absence of CNS Metastases,BIOLOGICAL: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells,Scott Pruitt,,INTERVENTIONAL,2013-07
NCT01983748,Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma,https://clinicaltrials.gov/study/NCT01983748,ACTIVE_NOT_RECRUITING,Uveal Melanoma,BIOLOGICAL: Autologous Dendritic Cells loaded with autologous Tumor RNA,University Hospital Erlangen,"University Hospital Lübeck|University Hospital Munich|Universitätsklinikum Hamburg-Eppendorf|University Hospital Homburg/Saar|Universitätsklinikum Köln|University Hospital Tuebingen|University Hospital, Essen|Wuerzburg University Hospital",INTERVENTIONAL,2023-12
NCT03092453,Dendritic Cell Vaccination in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT03092453,ACTIVE_NOT_RECRUITING,Melanoma,BIOLOGICAL: Mature dendritic cell (DC) vaccine|DRUG: Cyclophosphamide 300mg/m^2|DRUG: Pembrolizumab,University of Pennsylvania,,INTERVENTIONAL,2023-05
NCT00103142,Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer,https://clinicaltrials.gov/study/NCT00103142,COMPLETED,Colorectal Cancer|Metastatic Cancer,BIOLOGICAL: falimarev|BIOLOGICAL: inalimarev|BIOLOGICAL: sargramostim|BIOLOGICAL: therapeutic autologous dendritic cells,"Michael Morse, MD",National Cancer Institute (NCI),INTERVENTIONAL,2013-03
NCT02107391,Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer,https://clinicaltrials.gov/study/NCT02107391,COMPLETED,Prostate Cancer,BIOLOGICAL: Dendritic Cells DCVAC/PCa|DRUG: Leuprolide acetate|DRUG: Goserelin Acetate,SOTIO a.s.,,INTERVENTIONAL,2016-06
NCT05955157,Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma,https://clinicaltrials.gov/study/NCT05955157,RECRUITING,Pancreatic Ductal Adenocarcinoma|Advanced Solid Tumor,BIOLOGICAL: Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy|DRUG: Tegafur Only Product,University of Malaya,,INTERVENTIONAL,2025-06
NCT00436930,Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00436930,COMPLETED,Melanoma (Skin),BIOLOGICAL: autologous tumor cell vaccine|BIOLOGICAL: sargramostim|BIOLOGICAL: therapeutic autologous dendritic cells,Hoag Memorial Hospital Presbyterian,,INTERVENTIONAL,2012-10
NCT00510497,Autologous Dendritic Cell Vaccine in HIV1 Infection,https://clinicaltrials.gov/study/NCT00510497,COMPLETED,HIV Infections,BIOLOGICAL: Autologous HIV-1 ApB DC Vaccine,Sharon Riddler,National Institute of Allergy and Infectious Diseases (NIAID),INTERVENTIONAL,2012-09
NCT03679650,Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients,https://clinicaltrials.gov/study/NCT03679650,RECRUITING,Acute Myelogenous Leukemia,DRUG: decitabine|BIOLOGICAL: DC/AML fusion cells,Beth Israel Deaconess Medical Center,National Cancer Institute (NCI)|Dana-Farber Cancer Institute,INTERVENTIONAL,2026-08-31
NCT00612001,Vaccine Therapy in Treating Patients With Malignant Glioma,https://clinicaltrials.gov/study/NCT00612001,COMPLETED,Brain and Central Nervous System Tumors,BIOLOGICAL: glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,2012-10
NCT01587690,Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells,https://clinicaltrials.gov/study/NCT01587690,COMPLETED,Multiple Sclerosis,,"Rutgers, The State University of New Jersey",,OBSERVATIONAL,2013-01
NCT00053391,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00053391,COMPLETED,Melanoma (Skin),BIOLOGICAL: recombinant CD40-ligand|BIOLOGICAL: therapeutic autologous dendritic cells,University Hospital Erlangen,,INTERVENTIONAL,2007-06
NCT05786937,Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals,https://clinicaltrials.gov/study/NCT05786937,NOT_YET_RECRUITING,HIV Vaccine,BIOLOGICAL: Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|BIOLOGICAL: Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|OTHER: Commercial ringer´s lactate solution,University of Sao Paulo General Hospital,,INTERVENTIONAL,2023-12
NCT04530318,Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT04530318,RECRUITING,Relapsing-Remitting Multiple Sclerosis,OTHER: Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|OTHER: Placebo,Judit Pich,,INTERVENTIONAL,2025-06
NCT01635283,Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma,https://clinicaltrials.gov/study/NCT01635283,COMPLETED,Adult Diffuse Astrocytoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Tumor|Adult Oligoastrocytoma,BIOLOGICAL: tumor lysate-pulsed autologous dendritic cell vaccine|OTHER: laboratory biomarker analysis,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,2016-05-13
NCT00019929,Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00019929,COMPLETED,Lung Cancer,BIOLOGICAL: mutant p53 peptide pulsed dendritic cell vaccine|PROCEDURE: adjuvant therapy,National Cancer Institute (NCI),,INTERVENTIONAL,2005-12
NCT06036355,The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD),https://clinicaltrials.gov/study/NCT06036355,NOT_YET_RECRUITING,Postoperative Prevention of Tumor,DRUG: Oral NMN combined with DC cell vaccine,"Shanghai Cell Therapy Group Co.,Ltd",,INTERVENTIONAL,2024-12-30
NCT00476177,Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant,https://clinicaltrials.gov/study/NCT00476177,COMPLETED,Hematologic Malignancy,BIOLOGICAL: Infusion of donor dendritic cells|BIOLOGICAL: Infusion of donor lymphocytes,Dana-Farber Cancer Institute,Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|National Cancer Institute (NCI),INTERVENTIONAL,2009-07
NCT04299724,Safety and Immunity of Covid-19 aAPC Vaccine,https://clinicaltrials.gov/study/NCT04299724,RECRUITING,Treat and Prevent Covid-19 Infection,BIOLOGICAL: Pathogen-specific aAPC,Shenzhen Geno-Immune Medical Institute,Shenzhen Third People's Hospital|Shenzhen Second People's Hospital,INTERVENTIONAL,2024-12-31
NCT01568944,Role of Infected Blood Dendritic Cells in Heart Disease Risk,https://clinicaltrials.gov/study/NCT01568944,COMPLETED,Chronic Periodontitis,DRUG: Oral Antibiotic and Oral Rinse|PROCEDURE: Standard Treatment,Augusta University,National Institute of Dental and Craniofacial Research (NIDCR),INTERVENTIONAL,2014-09
NCT00338377,Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Immunization in Patients with Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00338377,ACTIVE_NOT_RECRUITING,Melanoma,BIOLOGICAL: Dendritic Cell Immunization|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: T-Cells|BIOLOGICAL: Interleukin-2|DRUG: Mesna|BIOLOGICAL: Intrathecal T-Cells|BIOLOGICAL: Intrathecal Interleukin-2,M.D. Anderson Cancer Center,"Prometheus Laboratories|Key Biologics, LLC|National Cancer Institute (NCI)|Adelson Medical Research",INTERVENTIONAL,2030-02-28
NCT00023985,Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00023985,COMPLETED,Lung Cancer,BIOLOGICAL: autologous tumor cell vaccine|BIOLOGICAL: therapeutic autologous dendritic cells|PROCEDURE: conventional surgery,Roswell Park Cancer Institute,,INTERVENTIONAL,2003-08
NCT01730118,Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,https://clinicaltrials.gov/study/NCT01730118,COMPLETED,Breast Neoplasms|Breast Cancer|Adenocarcinomas|Metastatic Solid Tumors Characterized by HER2/Neu Expression,BIOLOGICAL: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine,National Cancer Institute (NCI),,INTERVENTIONAL,2019-12-03
NCT02083393,Changes of Dendritic Cells in Acute Lung Injury,https://clinicaltrials.gov/study/NCT02083393,COMPLETED,Acute Lung Injury,,"Southeast University, China",,OBSERVATIONAL,2014-12
NCT06435910,Engineered Dendritic Cell Vaccines for Multiple Myeloma,https://clinicaltrials.gov/study/NCT06435910,RECRUITING,Multiple Myeloma or Plasmacytoma,BIOLOGICAL: DC vaccines,Shenzhen Geno-Immune Medical Institute,The No.2 Clinical Hospital of the Ministry of Health,INTERVENTIONAL,2027-12-31
NCT02993315,Melanoma Patients Immunized With Natural DenDritic Cells,https://clinicaltrials.gov/study/NCT02993315,ACTIVE_NOT_RECRUITING,Melanoma (Skin),BIOLOGICAL: nDC vaccination|BIOLOGICAL: placebo injection,Radboud University Medical Center,Dutch National Health Care Institute|ZonMw: The Netherlands Organisation for Health Research and Development,INTERVENTIONAL,2024-12
NCT00740896,Acute Effects of Smoking on Airway Dendritic Cells,https://clinicaltrials.gov/study/NCT00740896,COMPLETED,Tobacco Use Disorder,BEHAVIORAL: Smoking|BEHAVIORAL: Smoking,University of Rostock,German Research Foundation,INTERVENTIONAL,2008-12
NCT01935635,A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB,https://clinicaltrials.gov/study/NCT01935635,COMPLETED,Chronic Hepatitis B,BIOLOGICAL: HPDCs-T immune therapy,"Third Affiliated Hospital, Sun Yat-Sen University",Ruijin Hospital|Second People's Hospital of Yunnan Province,INTERVENTIONAL,2019-12
NCT05127824,Autologous Dendritic Cell Vaccine in Kidney Cancer,https://clinicaltrials.gov/study/NCT05127824,RECRUITING,"Carcinoma, Renal Cell",BIOLOGICAL: Autologous alpha-DC1/TBVA vaccine|DRUG: Cabozantinib,Jodi Maranchie,,INTERVENTIONAL,2026-12
NCT06006403,Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm,https://clinicaltrials.gov/study/NCT06006403,RECRUITING,Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Relapse Leukemia|Refractory Leukemia,BIOLOGICAL: CD123 targeted CAR-NK cells,"Chongqing Precision Biotech Co., Ltd",Shanxi Bethune Hospital,INTERVENTIONAL,2026-08-31
NCT01352858,Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA),https://clinicaltrials.gov/study/NCT01352858,COMPLETED,Rheumatoid Arthritis,DRUG: TolDC|DRUG: Arthroscopy & saline irrigation alone,Newcastle University,Arthritis Research UK|Newcastle-upon-Tyne Hospitals NHS Trust,INTERVENTIONAL,2018-11
NCT04690387,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection",https://clinicaltrials.gov/study/NCT04690387,COMPLETED,COVID-19,BIOLOGICAL: AV-COVID-19|OTHER: GM-CSF,"Aivita Biomedical, Inc.","PT AIVITA Biomedika Indonesia|Indonesia Ministry of Health|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",INTERVENTIONAL,2021-01-15
NCT01690377,Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients,https://clinicaltrials.gov/study/NCT01690377,COMPLETED,Melanoma,BIOLOGICAL: PDC or myDC,Radboud University Medical Center,,INTERVENTIONAL,2014-11
NCT01974661,Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT01974661,COMPLETED,Hepatocellular Carcinoma,BIOLOGICAL: COMBIG-DC (ilixadencel),Mendus,Uppsala University,INTERVENTIONAL,2017-06-28
NCT02496520,Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults,https://clinicaltrials.gov/study/NCT02496520,COMPLETED,Sarcoma|Central Nervous System Tumor,BIOLOGICAL: dendritic cells|PROCEDURE: Surgery as needed by the patient´s tumor and stage|DRUG: Chemotherapy as needed by the patient´s tumor and stage|RADIATION: Radiation therapy as needed by the patient´s tumor and stage,"Clinica Universidad de Navarra, Universidad de Navarra",,INTERVENTIONAL,2019-05-27
NCT01239875,"Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01239875,COMPLETED,Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Adult Diffuse Mixed Cell Lymphoma|Adult Diffuse Small Cleaved Cell Lymphoma|Adult Grade III Lymphomatoid Granulomatosis|Adult Immunoblastic Large Cell Lymphoma|Adult Lymphoblastic Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3 Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia With Nodal Disease,BIOLOGICAL: dendritic cell vaccine therapy|PROCEDURE: cryotherapy|BIOLOGICAL: pneumococcal polyvalent vaccine|OTHER: laboratory biomarker analysis|OTHER: immunoenzyme technique|OTHER: immunohistochemistry staining method|BIOLOGICAL: autologous dendritic cell-tumor fusion vaccine,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,2019-07-17
NCT02010606,Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,https://clinicaltrials.gov/study/NCT02010606,COMPLETED,Glioblastoma|Glioblastoma Multiforme|Glioma|Astrocytoma|Brain Tumor,"BIOLOGICAL: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|BIOLOGICAL: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab",Cedars-Sinai Medical Center,,INTERVENTIONAL,2021-07-10
NCT00001566,A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas,https://clinicaltrials.gov/study/NCT00001566,COMPLETED,Ewing's Sarcoma|Rhabdomyosarcoma,BIOLOGICAL: therapeutic autologous dendritic cells|DRUG: indinavir sulfate|PROCEDURE: peripheral blood stem cell transplantation,National Cancer Institute (NCI),,INTERVENTIONAL,2008-09
NCT00087984,RNA-Loaded Dendritic Cell Cancer Vaccine,https://clinicaltrials.gov/study/NCT00087984,COMPLETED,Renal Cell Carcinoma,BIOLOGICAL: MB-002,Argos Therapeutics,,INTERVENTIONAL,2008-09
NCT04135391,Aerobic Trainings on Stroke Patients,https://clinicaltrials.gov/study/NCT04135391,COMPLETED,"Stroke, Cardiovascular",BEHAVIORAL: Aerobic exercise training,Chang Gung Memorial Hospital,,INTERVENTIONAL,2018-06-30
NCT02961829,Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure,https://clinicaltrials.gov/study/NCT02961829,COMPLETED,Chronic Infection|HIV,DRUG: Maraviroc|DRUG: Dolutegravir|BIOLOGICAL: Dendritic Cell Vaccine|DRUG: Auranofin|DRUG: Sirtuin Histone deacetylase inhibitor,Federal University of São Paulo,Fundação de Amparo à Pesquisa do Estado de São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico|ViiV Healthcare,INTERVENTIONAL,2020-03
NCT01871467,Sargramostim for Myeloid Dendritic Cell Deficiency,https://clinicaltrials.gov/study/NCT01871467,COMPLETED,Dendritic Cell Deficiency,DRUG: Sargramostim,Johns Hopkins University,,INTERVENTIONAL,2014-06
NCT01711593,Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma,https://clinicaltrials.gov/study/NCT01711593,COMPLETED,Asthma|Allergies,"BIOLOGICAL: Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|PROCEDURE: Phlebotomy","Andrew D. Luster, M.D.,Ph.D.",National Institute of Allergy and Infectious Diseases (NIAID),INTERVENTIONAL,2016-09
NCT01213407,Dendritic Cell Cancer Vaccine for High-grade Glioma,https://clinicaltrials.gov/study/NCT01213407,COMPLETED,Glioblastoma Multiforme,"DRUG: Trivax, Temozolomide, Surgery, Radiotherapy|DRUG: Temozolomide, Surgery, Radiotherapy",Activartis Biotech,,INTERVENTIONAL,2015-11
NCT05451069,"Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple Sclerosis",https://clinicaltrials.gov/study/NCT05451069,NOT_YET_RECRUITING,Multiple Sclerosis,"DIAGNOSTIC_TEST: Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells",Assiut University,,OBSERVATIONAL,2025-07-27
NCT00107211,Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast,https://clinicaltrials.gov/study/NCT00107211,COMPLETED,Breast Cancer,BIOLOGICAL: therapeutic autologous dendritic cells|PROCEDURE: conventional surgery|PROCEDURE: neoadjuvant therapy,Abramson Cancer Center at Penn Medicine,National Cancer Institute (NCI),INTERVENTIONAL,2008-07
NCT01753089,Dendritic Cell Activating Scaffold in Melanoma,https://clinicaltrials.gov/study/NCT01753089,ACTIVE_NOT_RECRUITING,Melanoma,BIOLOGICAL: WDVAX,Dana-Farber Cancer Institute,,INTERVENTIONAL,2024-12-31
NCT00458536,Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF,https://clinicaltrials.gov/study/NCT00458536,COMPLETED,Renal Cancer,BIOLOGICAL: Dendritic Cell Tumor Fusion Vaccine|DRUG: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF),Beth Israel Deaconess Medical Center,National Cancer Institute (NCI)|Dana-Farber Cancer Institute,INTERVENTIONAL,2023-07
NCT00005956,Biological Therapy in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00005956,COMPLETED,Breast Cancer|Gastric Cancer|Ovarian Cancer,BIOLOGICAL: HER-2/neu intracellular domain protein|BIOLOGICAL: therapeutic autologous dendritic cells,Duke University,National Cancer Institute (NCI),INTERVENTIONAL,2002-07
NCT04627246,Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer,https://clinicaltrials.gov/study/NCT04627246,RECRUITING,Pancreatic Adenocarcinoma,BIOLOGICAL: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine),Centre Hospitalier Universitaire Vaudois,,INTERVENTIONAL,2028-09
NCT05304208,dENdritic Cell Therapy Combined With SURgEry in Mesothelioma,https://clinicaltrials.gov/study/NCT05304208,RECRUITING,Mesotheliomas Pleural,BIOLOGICAL: Mesopher,Erasmus Medical Center,,INTERVENTIONAL,2025-12-31
NCT01993004,Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells,https://clinicaltrials.gov/study/NCT01993004,COMPLETED,Multiple Sclerosis,,"Rutgers, The State University of New Jersey",,OBSERVATIONAL,2015-12
NCT00365872,External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma,https://clinicaltrials.gov/study/NCT00365872,COMPLETED,Soft Tissue Sarcoma,BIOLOGICAL: Dendritic Cell (DC) Injections|PROCEDURE: Radiation therapy|PROCEDURE: Complete Resection - Surgery for tumor removal,H. Lee Moffitt Cancer Center and Research Institute,Cancer Treatment Research Foundation,INTERVENTIONAL,2012-06
NCT02903537,Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS),https://clinicaltrials.gov/study/NCT02903537,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive",DRUG: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|DRUG: Interferon-beta,Fundació Institut Germans Trias i Pujol,"Clinica Universidad de Navarra, Universidad de Navarra",INTERVENTIONAL,2023-12
NCT06342908,A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma,https://clinicaltrials.gov/study/NCT06342908,NOT_YET_RECRUITING,"Diffuse Hemispheric Glioma, H3 G34-Mutant",PROCEDURE: Biospecimen Collection|BIOLOGICAL: Dendritic Cell Therapy|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|DRUG: Poly ICLC,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,2028-01-09
NCT01204684,Dendritic Cell Vaccine for Patients With Brain Tumors,https://clinicaltrials.gov/study/NCT01204684,COMPLETED,Glioma|Anaplastic Astrocytoma|Anaplastic Astro-oligodendroglioma|Glioblastoma,BIOLOGICAL: autologous tumor lysate-pulsed DC vaccination|BIOLOGICAL: Tumor lysate-pulsed DC vaccination+0.2% resiquimod|BIOLOGICAL: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,2024-08-21
NCT04208919,Delayed Infusion of DCreg in Living Donor Liver Transplantation,https://clinicaltrials.gov/study/NCT04208919,ACTIVE_NOT_RECRUITING,Living Donor Liver Transplantation,BIOLOGICAL: Donor-derived DCreg,Angus W. Thomson PhD DSc,,INTERVENTIONAL,2026-06
NCT00322959,Tai-Chi-Chuan on Differentiation and Maturation of Dendritic Cells,https://clinicaltrials.gov/study/NCT00322959,COMPLETED,Immunity,,Mackay Memorial Hospital,,OBSERVATIONAL,2006-11
NCT03803397,Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma,https://clinicaltrials.gov/study/NCT03803397,NOT_YET_RECRUITING,Metastatic Melanoma,BIOLOGICAL: PV-001-DC,PrimeVax Immuno-Oncology Inc.,,INTERVENTIONAL,2024-12-31
NCT00512889,Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma,https://clinicaltrials.gov/study/NCT00512889,COMPLETED,Melanoma (Skin),BIOLOGICAL: therapeutic autologous lymphocytes|GENETIC: Use of an artificial antigen presenting cell (aAPC) to generate CTL|DRUG: GM-CSF|RADIATION: Irradiation of cutaneous tumor lesion,Dana-Farber Cancer Institute,,INTERVENTIONAL,2013-01
NCT06296056,Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care,https://clinicaltrials.gov/study/NCT06296056,NOT_YET_RECRUITING,Colorectal Cancer Stage IV|Metastatic Colorectal Cancer,BIOLOGICAL: Combi,Nyamdavaa Tuul,,INTERVENTIONAL,2027-06-01
NCT03035331,"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT03035331,ACTIVE_NOT_RECRUITING,Aggressive Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma,PROCEDURE: Cryosurgery|BIOLOGICAL: Dendritic Cell Therapy|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Pneumococcal 13-valent Conjugate Vaccine|OTHER: Quality-of-Life Assessment,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,2025-08
NCT04619017,Airway Immune Response to Allergens (Use Lay Language Here),https://clinicaltrials.gov/study/NCT04619017,ACTIVE_NOT_RECRUITING,Allergic Asthma|Allergy to Cats|Allergy to Dust Mites|Allergic Rhinitis|Allergic Conjunctivitis,BIOLOGICAL: Segmental allergen challenge,JOSALYN CHO,Massachusetts General Hospital,INTERVENTIONAL,2024-03-01
NCT03416543,Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis,https://clinicaltrials.gov/study/NCT03416543,COMPLETED,Rheumatoid Arthritis|Gout|Osteoarthritis,OTHER: Puncture,"University Hospital, Tours",,OBSERVATIONAL,2021-12-08
NCT02049489,A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma,https://clinicaltrials.gov/study/NCT02049489,COMPLETED,Glioblastoma Multiforme,BIOLOGICAL: ICT-121 DC vaccine,Precision Life Sciences Group,,INTERVENTIONAL,2017-03
NCT00923351,"Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma",https://clinicaltrials.gov/study/NCT00923351,COMPLETED,"Neuroblastoma|Sarcoma|Rhabdomyosarcoma-Embryonal|Rhabdomyosarcoma- Alveolar|Neuroectodermal Tumors, Primitive, Peripheral",DRUG: Tumor Purged/CD25 Depleted Lymphocytes|BIOLOGICAL: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|DRUG: rhIL-7|BIOLOGICAL: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine,National Cancer Institute (NCI),,INTERVENTIONAL,2018-05-15
NCT05799612,Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma,https://clinicaltrials.gov/study/NCT05799612,RECRUITING,Angiosarcoma,DRUG: Paclitaxel|BIOLOGICAL: mRNA plus Lysate-loaded Dendritic Cell Vaccine|DRUG: PEGYLATED-INTERFERON ALPHA-2A|DRUG: Filgrastim,M.D. Anderson Cancer Center,Cancer Cures 4 Kids,INTERVENTIONAL,2029-12-31
NCT05430971,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry,https://clinicaltrials.gov/study/NCT05430971,RECRUITING,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),,Immune Oncology Research Institute,,OBSERVATIONAL,2032-07
NCT01876212,Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01876212,COMPLETED,Metastatic Melanoma,BIOLOGICAL: DC vaccine|DRUG: Dasatinib,Walter J. Storkus,National Cancer Institute (NCI),INTERVENTIONAL,2019-07-31
NCT00639639,Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,https://clinicaltrials.gov/study/NCT00639639,COMPLETED,Malignant Neoplasms of Brain,BIOLOGICAL: tetanus toxoid|BIOLOGICAL: therapeutic autologous dendritic cells|BIOLOGICAL: therapeutic autologous lymphocytes,Gary Archer Ph.D.,National Cancer Institute (NCI),INTERVENTIONAL,2022-06-01
NCT03384914,Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer,https://clinicaltrials.gov/study/NCT03384914,ACTIVE_NOT_RECRUITING,"Breast Cancer Female|Breast Cancer, Male|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III|Residual Disease|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma",BIOLOGICAL: DC1 Vaccine|BIOLOGICAL: WOKVAC Vaccine,H. Lee Moffitt Cancer Center and Research Institute,United States Department of Defense,INTERVENTIONAL,2026-12
NCT00723242,The Role of Dendritic Cells in Hepatitis C Infection,https://clinicaltrials.gov/study/NCT00723242,COMPLETED,Chronic Hepatitis C Infection,DRUG: Viraferon-peg and Rebetol,"University College, London",Schering-Plough,INTERVENTIONAL,2004-12
NCT00311272,Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT00311272,COMPLETED,Colorectal Neoplasms,BIOLOGICAL: MelCancerVac,"University Hospital, Gentofte, Copenhagen",,INTERVENTIONAL,2007-09
NCT00468182,Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00468182,COMPLETED,Multiple Sclerosis,DRUG: Interferon-beta 1b (Betaseron),"Rutgers, The State University of New Jersey",Bayer,OBSERVATIONAL,2011-12
NCT00074230,Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT00074230,COMPLETED,Melanoma (Skin),"BIOLOGICAL: Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin",University Hospital Erlangen,,INTERVENTIONAL,2014-03
NCT03974971,Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.,https://clinicaltrials.gov/study/NCT03974971,COMPLETED,Blastic Plasmacytoid Dendritic Cell Neoplasm,,Samsung Medical Center,,OBSERVATIONAL,2020-02-29
NCT00766753,Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas,https://clinicaltrials.gov/study/NCT00766753,COMPLETED,Malignant Glioma,BIOLOGICAL: Dendritic vaccine pulsed with multiple peptides|BIOLOGICAL: The first booster vaccine phase:|BIOLOGICAL: The second booster vaccine phase:,Frank Lieberman,"Oncovir, Inc.",INTERVENTIONAL,2016-06
NCT03879512,"Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG",https://clinicaltrials.gov/study/NCT03879512,COMPLETED,Childhood Glioblastoma,DRUG: depletion of regulatory T cells|PROCEDURE: reoperation|BIOLOGICAL: cancer vaccine|BIOLOGICAL: checkpoint blockade,Wuerzburg University Hospital,,INTERVENTIONAL,2024-07-31
NCT03697707,"Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia",https://clinicaltrials.gov/study/NCT03697707,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia in Remission,BIOLOGICAL: DCP-001,Mendus,"Amsterdam UMC, location VUmc",INTERVENTIONAL,2025-12
NCT03360708,Vaccine Therapy in Treating Patients With Recurrent Glioblastoma,https://clinicaltrials.gov/study/NCT03360708,COMPLETED,Giant Cell Glioblastoma|Recurrent Glioblastoma|Recurrent Gliosarcoma,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine,Mayo Clinic,,INTERVENTIONAL,2021-06-02
NCT02692976,Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients,https://clinicaltrials.gov/study/NCT02692976,COMPLETED,Prostatic Neoplasms|Immunotherapy|Dendritic Cells|Vaccines,BIOLOGICAL: mDC vaccination|BIOLOGICAL: pDC vaccination|BIOLOGICAL: mDC and pDC vaccination,Radboud University Medical Center,,INTERVENTIONAL,2019-03-06
NCT03942328,Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer,https://clinicaltrials.gov/study/NCT03942328,RECRUITING,Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma,BIOLOGICAL: Atezolizumab|BIOLOGICAL: Bevacizumab|RADIATION: External Beam Radiation Therapy|PROCEDURE: Pheresis|BIOLOGICAL: Pneumococcal 13-valent Conjugate Vaccine|BIOLOGICAL: Therapeutic Autologous Dendritic Cells,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,2028-02-29
NCT00515983,Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells,https://clinicaltrials.gov/study/NCT00515983,COMPLETED,Melanoma,BIOLOGICAL: DC/Apo-Nec,"José Mordoh, M.D., Ph.D.",,INTERVENTIONAL,2005-12
NCT02896543,The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction,https://clinicaltrials.gov/study/NCT02896543,COMPLETED,Acute Myocardial Infarction,OTHER: measurement,The First Affiliated Hospital of Dalian Medical University,,OBSERVATIONAL,2017-03
NCT04968366,Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery,https://clinicaltrials.gov/study/NCT04968366,ACTIVE_NOT_RECRUITING,Glioblastoma Multiforme of Brain,BIOLOGICAL: Autologous dendritic cells pulsed with multiple neoantigen peptides.|DRUG: Temozolomide adjuvant chemotherapy,Beijing Tiantan Hospital,ZhongSheng BioTech Inc.,INTERVENTIONAL,2024-12-31
NCT02767193,Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients,https://clinicaltrials.gov/study/NCT02767193,COMPLETED,HIV Infection,BIOLOGICAL: DCV3|BIOLOGICAL: DCV3 with PEG-INF|BIOLOGICAL: Placebo|BIOLOGICAL: Placebo with PEG-INF,Judit Pich Martínez,,INTERVENTIONAL,2019-05-22
NCT00630721,Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells,https://clinicaltrials.gov/study/NCT00630721,COMPLETED,Multiple Sclerosis,OTHER: IFNbeta-1b,"University of North Carolina, Chapel Hill",,INTERVENTIONAL,2011-03-15
NCT06152367,Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients,https://clinicaltrials.gov/study/NCT06152367,COMPLETED,Stage III Malignant Melanoma of Skin AJCC V6|Stage IV Malignant Melanoma of Skin,BIOLOGICAL: TAPCells vaccine,University of Chile,,INTERVENTIONAL,2004-10-09
NCT02661685,Safety Study of Adoptive Transfer of Autologous IKDC-like Cells,https://clinicaltrials.gov/study/NCT02661685,COMPLETED,Neoplasm Metastasis,BIOLOGICAL: autologous IKDC-like cells,"National Defense Medical Center, Taiwan","Ministry of Science and Technology, Taiwan|Academia Sinica, Taiwan",INTERVENTIONAL,2019-10
NCT02993302,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,https://clinicaltrials.gov/study/NCT02993302,COMPLETED,Graves Disease,DRUG: 1α-D3|DRUG: Placebos,Dr Cipto Mangunkusumo General Hospital,Indonesia University,INTERVENTIONAL,2015-03
NCT02111941,"Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",https://clinicaltrials.gov/study/NCT02111941,ACTIVE_NOT_RECRUITING,Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Tumor|Fallopian Tube Mucinous Neoplasm|Fallopian Tube Serous Neoplasm|Fallopian Tube Transitional Cell Carcinoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Transitional Cell Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine,Mayo Clinic,,INTERVENTIONAL,2025-06-30
NCT02574377,myDC/pDC in Stage III Melanoma Patients,https://clinicaltrials.gov/study/NCT02574377,COMPLETED,Melanoma,DRUG: A: myDC vaccination|DRUG: B: pDC vaccination|DRUG: C: combined myDC/pDC vaccination,Radboud University Medical Center,,INTERVENTIONAL,2021-09
NCT00493597,Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis,https://clinicaltrials.gov/study/NCT00493597,COMPLETED,Atherosclerosis|Restenosis,,"University Hospital, Antwerp",,OBSERVATIONAL,2020-10-26
NCT00003665,Vaccine Therapy in Treating Patients With Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00003665,COMPLETED,Melanoma (Skin),BIOLOGICAL: dendritic cell-MART-1 peptide vaccine|BIOLOGICAL: gp100 antigen|BIOLOGICAL: therapeutic tumor infiltrating lymphocytes|BIOLOGICAL: tyrosinase peptide,National Cancer Institute (NCI),,INTERVENTIONAL,2002-11
NCT00510133,A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML),https://clinicaltrials.gov/study/NCT00510133,COMPLETED,Acute Myelogenous Leukemia,BIOLOGICAL: GRNVAC1,"Asterias Biotherapeutics, Inc.",,INTERVENTIONAL,2014-08
NCT00908362,Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers,https://clinicaltrials.gov/study/NCT00908362,COMPLETED,Smoke-related Lung Diseases|Chronic Obstructive Pulmonary Disease,DRUG: fluticasone|DRUG: fluticasone/salmeterol|DRUG: placebo,University of Rostock,GlaxoSmithKline,INTERVENTIONAL,2009-12
NCT03371485,AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03371485,COMPLETED,Advanced Non-small Cell Lung Cancer,BIOLOGICAL: AST-VAC2,Cancer Research UK,,INTERVENTIONAL,2022-08-08
NCT00197522,Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2,https://clinicaltrials.gov/study/NCT00197522,COMPLETED,Breast Neoplasms,BIOLOGICAL: CD34+ derived DCs,Hamilton Health Sciences Corporation,Ontario Cancer Research Network|Canadian Breast Cancer Research Alliance|McMaster University,INTERVENTIONAL,2012-05
NCT00923910,Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood,https://clinicaltrials.gov/study/NCT00923910,COMPLETED,"Leukemia, Acute Myelogenous (AML)|Leukemia, Acute Lymphocytic (ALL)|Leukemia, Chronic Myelogenous (CML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma (NHL)",DRUG: WT1 Peptide-Pulsed Dendritic Cells|DRUG: Donor Lymphocytes|DRUG: IL-4|DRUG: KLH|DRUG: WT1 Peptides|DRUG: Endotoxin|DRUG: Diphenhydramine|DRUG: Acetaminophen,National Cancer Institute (NCI),,INTERVENTIONAL,2016-11-15
NCT04157127,Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma,https://clinicaltrials.gov/study/NCT04157127,ACTIVE_NOT_RECRUITING,Pancreatic Adenocarcinoma|Pancreatic Cancer,BIOLOGICAL: Autologous DC vaccine,Baylor College of Medicine,Cancer Cures for Kids,INTERVENTIONAL,2027-11
NCT02851056,Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT),https://clinicaltrials.gov/study/NCT02851056,COMPLETED,Multiple Myeloma,BIOLOGICAL: Survivin Vaccine|PROCEDURE: Autologous Hematopoietic Cell Transplantation|BIOLOGICAL: Prevnar 13|DRUG: Granulocyte-colony Stimulating Factor,H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL,2018-08-09
NCT05015426,Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT,https://clinicaltrials.gov/study/NCT05015426,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia,BIOLOGICAL: Gamma Delta T-Cell Infusion,H. Lee Moffitt Cancer Center and Research Institute,Florida Department of Health,INTERVENTIONAL,2026-09
NCT00237432,Study of the Immune Response to Hepatitis C Virus,https://clinicaltrials.gov/study/NCT00237432,COMPLETED,Hepatitis C,,Rockefeller University,,OBSERVATIONAL,2008-02
NCT03758625,Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure,https://clinicaltrials.gov/study/NCT03758625,ACTIVE_NOT_RECRUITING,HIV Infections,BIOLOGICAL: a1DC + inactivated whole autologous HIV|BIOLOGICAL: a1DC + conserved HIV peptides|BIOLOGICAL: a1DC + no antigen|BIOLOGICAL: pgDC + inactivated whole autologous HIV|BIOLOGICAL: pgDC + conserved HIV peptides|BIOLOGICAL: pgDC + no antigen,Sharon Riddler,National Institute of Allergy and Infectious Diseases (NIAID),INTERVENTIONAL,2025-03
NCT00478452,Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients,https://clinicaltrials.gov/study/NCT00478452,COMPLETED,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,BIOLOGICAL: DC-Ova|BIOLOGICAL: DC Ova with Cyclophosphamide,University of Pennsylvania,Fox Chase Cancer Center,INTERVENTIONAL,2008-08
NCT00050323,Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer,https://clinicaltrials.gov/study/NCT00050323,COMPLETED,"Carcinoma, Renal Cell",DRUG: Allogeneic DCs and Autologous RCC Tumor Derived Cells,"Genzyme, a Sanofi Company",,INTERVENTIONAL,2004-03
NCT06243289,Improving KIdney Transplantation With Cellular Therapy Study,https://clinicaltrials.gov/study/NCT06243289,RECRUITING,Immune Tolerance|Kidney Transplant Rejection,OTHER: Tolerance induction,Western Sydney Local Health District,,OBSERVATIONAL,2027-01-01
NCT04438564,Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients,https://clinicaltrials.gov/study/NCT04438564,RECRUITING,Breast Cancer|Colorectal Cancer|Cancer of Ovary|Cancer of Endometrium,"OTHER: Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer",China Medical University Hospital,,INTERVENTIONAL,2023-07-31
NCT00128622,Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer,https://clinicaltrials.gov/study/NCT00128622,COMPLETED,"Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: denileukin diftitox|BIOLOGICAL: recombinant fowlpox-CEA(6D)/TRICOM vaccine|BIOLOGICAL: therapeutic autologous dendritic cells,H. Kim Lyerly,National Cancer Institute (NCI),INTERVENTIONAL,2009-05
NCT02487550,DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating,https://clinicaltrials.gov/study/NCT02487550,NOT_YET_RECRUITING,Renal Neoplasma,BIOLOGICAL: DC-CIK|BIOLOGICAL: IL-2/IFN-α,The First People's Hospital of Changzhou,,INTERVENTIONAL,2030-07
NCT01957956,Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,https://clinicaltrials.gov/study/NCT01957956,COMPLETED,Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|DRUG: Temozolomide,Mayo Clinic,,INTERVENTIONAL,2016-11-16
NCT03119025,Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection,https://clinicaltrials.gov/study/NCT03119025,COMPLETED,"Hepatitis C, Chronic|Liver Diseases|Hepatitis|Virus Diseases",BIOLOGICAL: Autologous DC-vaccines,Russian Academy of Medical Sciences,,INTERVENTIONAL,2018-04
NCT04093323,"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma",https://clinicaltrials.gov/study/NCT04093323,RECRUITING,HLA-A2 Positive Cells Present|Refractory Melanoma,BIOLOGICAL: Alpha-type-1 Polarized Dendritic Cells|DRUG: Celecoxib|DRUG: PD-1 Ligand Inhibitor|DRUG: PD1 Inhibitor|BIOLOGICAL: Recombinant Interferon Alfa-2b|DRUG: Rintatolimod,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL,2025-11-22
NCT02678741,Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.,https://clinicaltrials.gov/study/NCT02678741,COMPLETED,Metastatic Melanoma,DRUG: TLPLDC Vaccine,"Elios Therapeutics, LLC",LumaBridge,INTERVENTIONAL,2019-11-13
NCT01280552,A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM),https://clinicaltrials.gov/study/NCT01280552,COMPLETED,Glioblastoma Multiforme,BIOLOGICAL: ICT-107|BIOLOGICAL: Placebo DC,Precision Life Sciences Group,,INTERVENTIONAL,2015-12
NCT02362464,Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139,https://clinicaltrials.gov/study/NCT02362464,COMPLETED,Prostatic Neoplasms|Neoplasms of Prostate|Prostate Cancer|Cancer Of Prostate|Stage D0 Prostate Cancer,BIOLOGICAL: Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine,National Cancer Institute (NCI),,INTERVENTIONAL,2022-03-25
NCT02285413,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,https://clinicaltrials.gov/study/NCT02285413,COMPLETED,Melanoma,BIOLOGICAL: DC vaccination|BIOLOGICAL: DC vaccination with cisplatinum,Radboud University Medical Center,,INTERVENTIONAL,2016-04
NCT03334305,Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas,https://clinicaltrials.gov/study/NCT03334305,ACTIVE_NOT_RECRUITING,Malignant Glioma|High Grade Glioma,BIOLOGICAL: TTRNA-DC vaccines with GM-CSF|DRUG: Dose-intensified TMZ|BIOLOGICAL: Autologous Hematopoietic Stem cells (HSCs)|BIOLOGICAL: TTRNA-xALT|DRUG: Td vaccine,University of Florida,National Pediatric Cancer Foundation|National Cancer Institute (NCI)|Moffitt Clinical Research Network (MCRN)|National Institutes of Health (NIH),INTERVENTIONAL,2028-05
NCT04739527,"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment",https://clinicaltrials.gov/study/NCT04739527,ACTIVE_NOT_RECRUITING,Ovarian Cancer,BIOLOGICAL: DCP-001,University Medical Center Groningen,Mendus,INTERVENTIONAL,2026-06-01
NCT05399433,Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis,https://clinicaltrials.gov/study/NCT05399433,RECRUITING,Psoriasis,OTHER: Biopsy and venous blood,Centre Hospitalier Universitaire de Nice,,INTERVENTIONAL,2026-09-01
NCT02479230,Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients,https://clinicaltrials.gov/study/NCT02479230,COMPLETED,Breast Cancer|Metastatic Breast Cancer,BIOLOGICAL: tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|DRUG: gemcitabine hydrochloride,"Joseph Baar, MD, PhD",,INTERVENTIONAL,2022-07-01
NCT00499083,"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)",https://clinicaltrials.gov/study/NCT00499083,COMPLETED,Breast Cancer,BIOLOGICAL: therapeutic autologous dendritic cells|DRUG: aromatase inhibition therapy|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: paclitaxel|DRUG: tamoxifen citrate|GENETIC: gene expression analysis|GENETIC: protein expression analysis|GENETIC: reverse transcriptase-polymerase chain reaction|OTHER: immunoenzyme technique|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis|PROCEDURE: adjuvant therapy|PROCEDURE: biopsy|PROCEDURE: conventional surgery|PROCEDURE: neoadjuvant therapy|RADIATION: radiation therapy,University of Nebraska,National Cancer Institute (NCI),INTERVENTIONAL,2010-01-28
NCT05539365,Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer,https://clinicaltrials.gov/study/NCT05539365,NOT_YET_RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma,BIOLOGICAL: Alpha-type-1 Polarized Dendritic Cells|PROCEDURE: Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Leukapheresis|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment,Roswell Park Cancer Institute,,INTERVENTIONAL,2026-10-01
NCT01995708,"CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",https://clinicaltrials.gov/study/NCT01995708,COMPLETED,Multiple Myeloma,"BIOLOGICAL: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|OTHER: Standard of care",Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,2022-06-20
NCT02159937,In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides,https://clinicaltrials.gov/study/NCT02159937,COMPLETED,Metastatic Cancer,OTHER: Blood sampling by vena punction.,Recepta Biopharma,,OBSERVATIONAL,2014-12
NCT01373515,Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT01373515,COMPLETED,Acute Myeloid Leukemia (AML)|Leukemic Dendritic Cell Vaccination,BIOLOGICAL: DCP-001,Mendus,,INTERVENTIONAL,2013-05
NCT05100641,AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM,https://clinicaltrials.gov/study/NCT05100641,NOT_YET_RECRUITING,Primary Glioblastoma,BIOLOGICAL: AV-GBM-1|BIOLOGICAL: Autologous monocytes,"Aivita Biomedical, Inc.",,INTERVENTIONAL,2029-03
NCT02611180,Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease,https://clinicaltrials.gov/study/NCT02611180,RECRUITING,Acute Graft-versus-host Disease|Acute GVHD|Chronic Graft-versus-host Disease|Chronic GVHD,PROCEDURE: Skin punch biopsy|PROCEDURE: Peripheral blood draw,Washington University School of Medicine,,OBSERVATIONAL,2025-04-30
NCT00004604,Biological Therapy in Treating Patients With Metastatic Cancer,https://clinicaltrials.gov/study/NCT00004604,COMPLETED,Breast Cancer|Colorectal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Lung Cancer|Metastatic Cancer|Ovarian Cancer|Pancreatic Cancer|Testicular Germ Cell Tumor,BIOLOGICAL: CEA RNA-pulsed DC cancer vaccine,Duke University,National Cancer Institute (NCI),INTERVENTIONAL,2002-07
NCT00320164,Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals,https://clinicaltrials.gov/study/NCT00320164,COMPLETED,Healthy,,Weill Medical College of Cornell University,,OBSERVATIONAL,2008-01
NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,https://clinicaltrials.gov/study/NCT01863108,COMPLETED,Melanoma|Tumor Vaccines|Effects of Immunotherapy,BIOLOGICAL: GeniusVac-Mel4,"University Hospital, Grenoble","Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France|Université Joseph Fourier",INTERVENTIONAL,2017-03-23
NCT02113982,Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT02113982,COMPLETED,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Acute Myeloid Leukemia (AML),DRUG: Tagraxofusp,"Stemline Therapeutics, Inc.",The Leukemia and Lymphoma Society,INTERVENTIONAL,2020-03-12
NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,https://clinicaltrials.gov/study/NCT02018458,COMPLETED,Breast Cancer,BIOLOGICAL: LA TNBC: DC vaccine+Preop chemo|BIOLOGICAL: ER+/HER2-BC:DC vaccine+Preop chemo,Baylor Research Institute,,INTERVENTIONAL,2019-09-18
NCT05650918,MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial),https://clinicaltrials.gov/study/NCT05650918,COMPLETED,Metastatic Pancreatic Cancer,BIOLOGICAL: MesoPher|BIOLOGICAL: Mitazalimab,"Joachim Aerts, MD PhD",,INTERVENTIONAL,2023-05-23
NCT05457959,"Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant",https://clinicaltrials.gov/study/NCT05457959,NOT_YET_RECRUITING,"Diffuse Hemispheric Glioma, H3 G34-Mutant",BIOLOGICAL: Dendritic Cell Tumor Peptide Vaccine|BIOLOGICAL: Ipilimumab|PROCEDURE: Leukapheresis|BIOLOGICAL: Nivolumab|DRUG: Placebo Administration|DRUG: Placebo Administration|DRUG: Poly ICLC|PROCEDURE: Resection,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,2030-05-01
NCT00625989,The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics,https://clinicaltrials.gov/study/NCT00625989,COMPLETED,Asthma,DRUG: Aeroallergen,Hamilton Health Sciences Corporation,,INTERVENTIONAL,2008-12
NCT01241682,Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT01241682,COMPLETED,Malignant (Pleural) Mesothelioma,BIOLOGICAL: DC + CTX,Erasmus Medical Center,,INTERVENTIONAL,2012-10
NCT05195619,Personalized DC Vaccines in Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT05195619,RECRUITING,Non-small Cell Lung Cancer,BIOLOGICAL: Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|DRUG: Low dose cyclophosphamide,Centre Hospitalier Universitaire Vaudois,,INTERVENTIONAL,2024-09
NCT02301611,Phase IIB TL + YCWP + DC in Melanoma,https://clinicaltrials.gov/study/NCT02301611,COMPLETED,Melanoma,DRUG: TLPLDC|DRUG: Placebo,"Cancer Insight, LLC","Elios Therapeutics, LLC",INTERVENTIONAL,2022-05-11
NCT00279058,The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2,https://clinicaltrials.gov/study/NCT00279058,COMPLETED,Metastatic Melanoma,PROCEDURE: Immunotherapy treatment for melanoma,Hadassah Medical Organization,,INTERVENTIONAL,2008-12
NCT00404339,Vaccine Therapy in Treating Patients With Head and Neck Cancer,https://clinicaltrials.gov/study/NCT00404339,COMPLETED,Head and Neck Cancer,BIOLOGICAL: mutant p53 peptide pulsed dendritic cell vaccine|BIOLOGICAL: tetanus toxoid helper peptide|PROCEDURE: adjuvant therapy,Robert Ferris,National Cancer Institute (NCI),INTERVENTIONAL,2014-03
NCT03450122,"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma",https://clinicaltrials.gov/study/NCT03450122,COMPLETED,HLA-A*0201 Positive Cells Present|NY-ESO-1 Positive Tumor Cells Present|Recurrent Myxoid Liposarcoma|Recurrent Synovial Sarcoma,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|DRUG: Cyclophosphamide|BIOLOGICAL: Dendritic Cell-targeting Lentiviral Vector ID-LV305,M.D. Anderson Cancer Center,,INTERVENTIONAL,2022-12-06
NCT00912574,Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38,https://clinicaltrials.gov/study/NCT00912574,COMPLETED,Melanoma,DRUG: GM-CSF-in-adjuvant|DRUG: Montanide ISA-51|BIOLOGICAL: GM-CSF and Montanide ISA-51|DRUG: Saline,University of Virginia,,INTERVENTIONAL,
NCT05411497,Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT05411497,RECRUITING,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,BIOLOGICAL: Autologous MUC1-activated T-cells|DRUG: Cyclophosphamide,Mayo Clinic,,INTERVENTIONAL,2025-10-01
NCT03895996,"Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes",https://clinicaltrials.gov/study/NCT03895996,COMPLETED,Type 1 Diabetes Mellitus,DRUG: AVT001|OTHER: Placebo,Avotres Inc.,,INTERVENTIONAL,2023-12-19
NCT03592888,DC Vaccine in Pancreatic Cancer,https://clinicaltrials.gov/study/NCT03592888,COMPLETED,Pancreatic Ductal Adenocarcinoma,DRUG: mDC3/8-KRAS Vaccine,University of Pennsylvania,,INTERVENTIONAL,2024-02-12
NCT00003792,Vaccine Therapy in Treating Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00003792,COMPLETED,Melanoma (Skin),BIOLOGICAL: MART-1 antigen|BIOLOGICAL: filgrastim|BIOLOGICAL: flu matrix peptide p58-66|BIOLOGICAL: gp100 antigen|BIOLOGICAL: recombinant MAGE-3.1 antigen|BIOLOGICAL: tyrosinase peptide|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation,Baylor Health Care System,National Cancer Institute (NCI),INTERVENTIONAL,2006-10
NCT00698776,Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma,https://clinicaltrials.gov/study/NCT00698776,COMPLETED,Myeloma,DRUG: Lenalidomide|BIOLOGICAL: Monocyte derived DCs loaded with KRN7000,Yale University,"Kyowa Kirin Co., Ltd.|Celgene",INTERVENTIONAL,2011-05
NCT01885702,Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI,https://clinicaltrials.gov/study/NCT01885702,ACTIVE_NOT_RECRUITING,Colorectal Cancer,BIOLOGICAL: DC vaccination,Radboud University Medical Center,,INTERVENTIONAL,2024-12
NCT05325632,"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab",https://clinicaltrials.gov/study/NCT05325632,RECRUITING,HER2-positive Breast Cancer,BIOLOGICAL: HER-2 pulsed DC1|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Paclitaxel|PROCEDURE: Resection surgery,H. Lee Moffitt Cancer Center and Research Institute,ImmunoRestoration,INTERVENTIONAL,2025-01-31
NCT01159288,Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes,https://clinicaltrials.gov/study/NCT01159288,COMPLETED,Non Small Cell Lung Cancer,BIOLOGICAL: Dex2,"Gustave Roussy, Cancer Campus, Grand Paris",,INTERVENTIONAL,2015-12-19
NCT01395056,Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients,https://clinicaltrials.gov/study/NCT01395056,COMPLETED,Breast Neoplasms|Neoplasm Metastasis,,Peking University Cancer Hospital & Institute,,OBSERVATIONAL,2015-06
NCT03990493,Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma,https://clinicaltrials.gov/study/NCT03990493,NOT_YET_RECRUITING,Advanced Melanoma,BIOLOGICAL: Dengue Virus-1 #45AZ5 (PV-001-DV)|BIOLOGICAL: Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC),PrimeVax Immuno-Oncology Inc.,Walter Reed Army Institute of Research (WRAIR),INTERVENTIONAL,2024-12-31
NCT06026202,Non-Eosinophilic Biological Effects of IL-5,https://clinicaltrials.gov/study/NCT06026202,RECRUITING,Asthma,,Imperial College London,,OBSERVATIONAL,2024-09-30
NCT02159495,Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm,https://clinicaltrials.gov/study/NCT02159495,ACTIVE_NOT_RECRUITING,Adult Acute Myeloid Leukemia in Remission|Acute Biphenotypic Leukemia|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Acute Myeloid Leukemia|Adult Acute Lymphoblastic Leukemia|Interleukin-3 Receptor Subunit Alpha Positive|Minimal Residual Disease|Refractory Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: cyclophosphamide|BIOLOGICAL: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|OTHER: laboratory biomarker analysis|BIOLOGICAL: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|DRUG: Fludarabine Phosphate,City of Hope Medical Center,"National Cancer Institute (NCI)|Mustang Bio, Inc.",INTERVENTIONAL,2024-12-15
NCT00100906,Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer,https://clinicaltrials.gov/study/NCT00100906,COMPLETED,Kidney Cancer,DRUG: IL-2|DRUG: ATRA,H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI)|National Institutes of Health (NIH)|Chiron Corporation,INTERVENTIONAL,2013-07
NCT05007496,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19",https://clinicaltrials.gov/study/NCT05007496,COMPLETED,COVID-19,BIOLOGICAL: AV-COVID-19,"Aivita Biomedical, Inc.",PT AIVITA Biomedika Indonesia|Kariadi Hospital|Central Army Hospital RSPAD Gatot Soebroto,INTERVENTIONAL,2021-05-31
NCT06046144,Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors,https://clinicaltrials.gov/study/NCT06046144,COMPLETED,Basal Cell Carcinoma|Lentigo Maligna|Melanoma|Nevus|Seborrheic Keratosis|Lentigo,DIAGNOSTIC_TEST: Fluorescence-Advanced videodermatoscopy|DIAGNOSTIC_TEST: Reflectance confocal microscopy|DIAGNOSTIC_TEST: Super-high magnification dermoscopy,Centre Hospitalier Universitaire de Saint Etienne,,OBSERVATIONAL,2023-05-01
NCT04214717,Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor,https://clinicaltrials.gov/study/NCT04214717,RECRUITING,Solid Tumor,COMBINATION_PRODUCT: DC-CIK combined with Chemotherapy|DRUG: Chemotherapy,Yantai Yuhuangding Hospital,,INTERVENTIONAL,2024-12-31
NCT01123265,National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study,https://clinicaltrials.gov/study/NCT01123265,COMPLETED,Psoriatic Arthritis,DRUG: Methotrexate|DRUG: Anti-TNF,University of Rochester,National Psoriasis Foundation,OBSERVATIONAL,2014-06
NCT04837547,PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy,https://clinicaltrials.gov/study/NCT04837547,RECRUITING,Neuroblastoma|Diffuse Intrinsic Pontine Glioma,BIOLOGICAL: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT),University of Florida,Beat Childhood Cancer Research Consortium,INTERVENTIONAL,2030-09
NCT01042535,Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT01042535,COMPLETED,"Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: adenovirus-p53 transduced dendritic cell (DC) vaccine|DRUG: 1-methyl-d-tryptophan|OTHER: Laboratory biomarker analysis,H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI),INTERVENTIONAL,2018-02-27
NCT00289341,Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.,https://clinicaltrials.gov/study/NCT00289341,COMPLETED,Prostate Cancer,BIOLOGICAL: vaccine vehicle only|BIOLOGICAL: DC/LNCaP,Rockefeller University,,INTERVENTIONAL,2008-11
NCT03788083,Intratumoral TriMix Injections in Early Breast Cancer Patients,https://clinicaltrials.gov/study/NCT03788083,RECRUITING,Breast Cancer Female|Early-stage Breast Cancer,DRUG: Trimix|DRUG: Placebo,Universitair Ziekenhuis Brussel,eTheRNA immunotherapies,INTERVENTIONAL,2024-12-30
NCT00334776,Vaccine Therapy in Treating Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00334776,COMPLETED,Intraocular Melanoma|Melanoma (Skin),BIOLOGICAL: MART-1 antigen|BIOLOGICAL: gp100:209-217(210M) peptide vaccine|BIOLOGICAL: therapeutic autologous dendritic cells|BIOLOGICAL: tyrosinase peptide,University of Southern California,National Cancer Institute (NCI),INTERVENTIONAL,2005-06
NCT00683241,A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer,https://clinicaltrials.gov/study/NCT00683241,COMPLETED,Ovarian Cancer|Peritoneal Cancer,BIOLOGICAL: DCVac-L,Abramson Cancer Center at Penn Medicine,"Northwest Biotherapeutics|University of California, San Francisco",INTERVENTIONAL,2009-12
NCT06370026,KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial,https://clinicaltrials.gov/study/NCT06370026,NOT_YET_RECRUITING,Nasopharyngeal Carcinoma,BIOLOGICAL: KSD-101,Sun Yat-sen University,"Kousai Bio Co., Ltd.",INTERVENTIONAL,2026-12-31
NCT00558051,Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT00558051,COMPLETED,Metastatic Colorectal Cancer,BIOLOGICAL: DC-based vaccine|BIOLOGICAL: DC-based vaccine|BIOLOGICAL: DC-based vaccine,Pawel Kalinski,,INTERVENTIONAL,2014-04
NCT03743298,Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma,https://clinicaltrials.gov/study/NCT03743298,RECRUITING,Metastatic Melanoma,DRUG: AV-MEL-1,"Aivita Biomedical, Inc.",,INTERVENTIONAL,2026-05
NCT03485547,"Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",https://clinicaltrials.gov/study/NCT03485547,ACTIVE_NOT_RECRUITING,Blastic Plasmacytoid Dendritic Cell Neoplasm,DRUG: Venetoclax,Dana-Farber Cancer Institute,AbbVie,INTERVENTIONAL,2025-01-19
NCT03360630,Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC,https://clinicaltrials.gov/study/NCT03360630,COMPLETED,Lung Cancer|Neoplasms,BIOLOGICAL: Anti-PD-1 plus DC-CIK|BIOLOGICAL: Anti-PD-1 alone,Capital Medical University,Duke University|Geneplus-Beijing Co. Ltd.,INTERVENTIONAL,2023-06-01
NCT01096602,Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission,https://clinicaltrials.gov/study/NCT01096602,ACTIVE_NOT_RECRUITING,Acute Myelogenous Leukemia|AML,BIOLOGICAL: DC AML Vaccine,Beth Israel Deaconess Medical Center,"National Institutes of Health (NIH)|Medivation, Inc.|The Leukemia and Lymphoma Society|Dana-Farber Cancer Institute",INTERVENTIONAL,2024-06
NCT00083538,Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally,https://clinicaltrials.gov/study/NCT00083538,COMPLETED,Multiple Myeloma,DRUG: Dexamethasone|DRUG: Thalidomide|DRUG: Cisplatinum|DRUG: Adriamycin|DRUG: Cyclophosphamide|DRUG: Etoposide,University of Arkansas,,INTERVENTIONAL,2007-12
NCT04216524,"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm",https://clinicaltrials.gov/study/NCT04216524,RECRUITING,Blastic Plasmacytoid Dendritic Cell Neoplasm,DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Methylprednisolone|DRUG: Prednisone|BIOLOGICAL: Rituximab|BIOLOGICAL: Tagraxofusp-erzs|DRUG: Venetoclax|DRUG: Vincristine,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,2026-12-31
NCT01987609,Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques,https://clinicaltrials.gov/study/NCT01987609,COMPLETED,Psoriasis,DRUG: Hylenex|DRUG: Normal Saline,"Tissa Hata, MD",,INTERVENTIONAL,2018-02
NCT00003993,Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00003993,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: aldesleukin|DRUG: bryostatin 1,National Institute on Aging (NIA),National Cancer Institute (NCI),INTERVENTIONAL,
NCT01671592,Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI),https://clinicaltrials.gov/study/NCT01671592,COMPLETED,"Colorectal Neoplasms|Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal",BIOLOGICAL: DC Vaccine,Pawel Kalinski,National Cancer Institute (NCI),INTERVENTIONAL,2014-04
NCT01657734,Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy,https://clinicaltrials.gov/study/NCT01657734,COMPLETED,Malignant Gliomas,OTHER: MR imaging,Universitaire Ziekenhuizen KU Leuven,,OBSERVATIONAL,2016-02-18
NCT00779402,PROvenge Treatment and Early Cancer Treatment,https://clinicaltrials.gov/study/NCT00779402,COMPLETED,Prostate Cancer,OTHER: Control|BIOLOGICAL: Sipuleucel-T,Dendreon,,INTERVENTIONAL,2015-05
NCT00027534,Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer,https://clinicaltrials.gov/study/NCT00027534,COMPLETED,Breast Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Ovarian Cancer|Pancreatic Cancer|Testicular Germ Cell Tumor,BIOLOGICAL: TRICOM-CEA(6D),"Michael Morse, MD",National Cancer Institute (NCI),INTERVENTIONAL,2007-10
NCT02859623,Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN),https://clinicaltrials.gov/study/NCT02859623,COMPLETED,Blastic Plasmacytoid Dendritic Cell Neoplasm|Hematological Malignancies,,Centre Hospitalier Universitaire de Besancon,,OBSERVATIONAL,
NCT06097793,KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial,https://clinicaltrials.gov/study/NCT06097793,RECRUITING,Nasopharyngeal Carcinoma,BIOLOGICAL: KSD-101,"Kousai Bio Co., Ltd.",,INTERVENTIONAL,2025-12-31
NCT01697527,Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT01697527,ACTIVE_NOT_RECRUITING,Malignant Neoplasm,BIOLOGICAL: aldesleukin|DRUG: fludarabine phosphate|DRUG: cyclophosphamide|OTHER: laboratory biomarker analysis|BIOLOGICAL: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|BIOLOGICAL: dendritic cell vaccine therapy|RADIATION: fludeoxyglucose F 18|PROCEDURE: positron emission tomography,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL,2025-11-02
NCT05920798,A Study of FRaDCs for Ovarian Cancer,https://clinicaltrials.gov/study/NCT05920798,RECRUITING,Fallopian Tube Carcinosarcoma|Primary Peritoneal Carcinosarcoma|Recurrent Fallopian Tube Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube High Grade Serous Adenocarcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Carcinosarcoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian High Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|BIOLOGICAL: Pembrolizumab|PROCEDURE: Pheresis,Mayo Clinic,NanoPass Technologies Ltd,INTERVENTIONAL,2027-07-15
NCT00678119,Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment,https://clinicaltrials.gov/study/NCT00678119,COMPLETED,Renal Cell Carcinoma,BIOLOGICAL: AGS-003|DRUG: Sunitinib,Argos Therapeutics,,INTERVENTIONAL,2012-05
NCT05000801,Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT05000801,RECRUITING,Acute Myeloid Leukemia,BIOLOGICAL: DC vaccine,Affiliated Hospital to Academy of Military Medical Sciences,,INTERVENTIONAL,2026-07-01
NCT01884168,Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy,https://clinicaltrials.gov/study/NCT01884168,COMPLETED,Malignant Tumor,BIOLOGICAL: Dc-CIK immunotherapy,Capital Medical University,,OBSERVATIONAL,2023-05
NCT01781520,Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer,https://clinicaltrials.gov/study/NCT01781520,COMPLETED,Pancreatic Cancer,BIOLOGICAL: DC-CIK Treatment|DRUG: S1|OTHER: Best supportive care,Capital Medical University,,INTERVENTIONAL,2017-06-13
NCT04166006,A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.,https://clinicaltrials.gov/study/NCT04166006,RECRUITING,Head Neck Tumors|Neuroendocrine Tumors|Soft Tissue Sarcoma|Rare Cancer|Vaccination,BIOLOGICAL: Autologous DC vaccine|DRUG: Interleukin-2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,INTERVENTIONAL,2031-12
NCT02533895,Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood,https://clinicaltrials.gov/study/NCT02533895,COMPLETED,Childhood Solid Tumor,BIOLOGICAL: AV0113 DC-CIT|OTHER: Data evaluation,Activartis Biotech,,INTERVENTIONAL,2015-10
NCT01783951,Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer,https://clinicaltrials.gov/study/NCT01783951,COMPLETED,Gastric Cancer,BIOLOGICAL: DC-CIK|DRUG: S-1|DRUG: Cisplatin,Capital Medical University,Duke University|Geneplus-Beijing Co. Ltd.,INTERVENTIONAL,2018-06-01
NCT01477749,Sipuleucel-T Manufacturing Demonstration Study,https://clinicaltrials.gov/study/NCT01477749,COMPLETED,"Cancer of Prostate|Cancer of the Prostate|Neoplasms, Prostate|Neoplasms, Prostatic|Prostate Cancer|Prostate Neoplasms|Prostatic Cancer",BIOLOGICAL: sipuleucel-T,Dendreon,,INTERVENTIONAL,2014-06
NCT02491697,Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT02491697,ACTIVE_NOT_RECRUITING,Breast Cancer,BIOLOGICAL: DC-CIK Immunotherapy|DRUG: Capecitabine Monotherapy,The First People's Hospital of Changzhou,,INTERVENTIONAL,2033-08
NCT00374049,MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer,https://clinicaltrials.gov/study/NCT00374049,COMPLETED,Prostate Cancer,DRUG: MUC_1,Olivera Finn,"Oncovir, Inc.",INTERVENTIONAL,2015-12
NCT05877651,MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.,https://clinicaltrials.gov/study/NCT05877651,COMPLETED,Solid Tumors,BIOLOGICAL: MASCT-I injection,HRYZ Biotech Co.,,INTERVENTIONAL,2021-10-15
NCT02599415,Anti-psoriatic Effect of TL01 Light Therapy,https://clinicaltrials.gov/study/NCT02599415,COMPLETED,Psoriasis,DEVICE: TL01 light treatment,University of Aberdeen,NHS Grampian,INTERVENTIONAL,2014-12
NCT05749627,Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors,https://clinicaltrials.gov/study/NCT05749627,RECRUITING,Advanced Malignant Solid Tumors,DRUG: Neoantigen peptide vaccine|DRUG: Neoantigen-based DC immune preparation,The First Affiliated Hospital of Nanchang University,Shanghai Dengding BioAI Co.,INTERVENTIONAL,2025-12-31
NCT00003222,Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00003222,COMPLETED,Melanoma (Skin),BIOLOGICAL: aldesleukin|BIOLOGICAL: gp100 antigen|BIOLOGICAL: incomplete Freund's adjuvant|BIOLOGICAL: sargramostim|BIOLOGICAL: tetanus peptide melanoma vaccine|BIOLOGICAL: tyrosinase peptide,University of Virginia,National Cancer Institute (NCI),INTERVENTIONAL,
NCT01686334,Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission,https://clinicaltrials.gov/study/NCT01686334,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia,BIOLOGICAL: DC vaccine,Zwi Berneman,Kom Op Tegen Kanker|Stichting tegen Kanker|Research Foundation Flanders,INTERVENTIONAL,2027-12
NCT03059485,DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,https://clinicaltrials.gov/study/NCT03059485,COMPLETED,Acute Myelogenous Leukemia,BIOLOGICAL: DC/AML Fusion Vaccine|OTHER: Observation,Beth Israel Deaconess Medical Center,Celgene|Dana-Farber Cancer Institute,INTERVENTIONAL,2024-09-23
NCT02686944,A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors,https://clinicaltrials.gov/study/NCT02686944,COMPLETED,Gastrointestinal Stromal Tumor,BIOLOGICAL: Intuvax (ilixadencel),Mendus,,INTERVENTIONAL,2019-05-10
NCT01734304,DC Vaccination for Postremission Therapy in AML,https://clinicaltrials.gov/study/NCT01734304,COMPLETED,Acute Myeloid Leukemia,BIOLOGICAL: DC vaccination for postremission therapy in AML,Ludwig-Maximilians - University of Munich,,INTERVENTIONAL,2018-09-30
NCT06277154,MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma,https://clinicaltrials.gov/study/NCT06277154,NOT_YET_RECRUITING,Leiomyosarcoma|Liposarcoma|Synovial Sarcoma|Angiosarcoma|Undifferentiated Pleomorphic Sarcoma|Epithelioid Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Fibrosarcoma|Pleomorphic Rhabdomyosarcoma|Endometrial Stromal Sarcoma|Desmoplastic Small Round Cell Tumor,BIOLOGICAL: MASCT-I|DRUG: Doxorubicin|DRUG: Ifosfamide,HRYZ Biotech Co.,,INTERVENTIONAL,2027-02
NCT00715078,To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen,https://clinicaltrials.gov/study/NCT00715078,COMPLETED,Prostate Cancer,BIOLOGICAL: sipuleucel-T,Dendreon,,INTERVENTIONAL,2015-05
NCT04834544,A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care,https://clinicaltrials.gov/study/NCT04834544,RECRUITING,Epithelial Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma,COMBINATION_PRODUCT: DCVAC/OvCa|COMBINATION_PRODUCT: Placebo,Peking University Third Hospital,SOTIO a.s.,INTERVENTIONAL,2027-04-20
NCT01074840,Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy,https://clinicaltrials.gov/study/NCT01074840,COMPLETED,Peanut Allergy,OTHER: Peanut flour,University of Texas Southwestern Medical Center,,INTERVENTIONAL,2014-08
NCT04948099,A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases,https://clinicaltrials.gov/study/NCT04948099,COMPLETED,Dendritic Cell -Mediated Rheumatic Diseases,DRUG: VIB1116|DRUG: Placebo,Viela Bio (acquired by Horizon Therapeutics),,INTERVENTIONAL,2023-07-03
NCT06471673,A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer,https://clinicaltrials.gov/study/NCT06471673,RECRUITING,"Breast Cancer|Breast Tumor|Cancer of Breast|Cancer of the Breast|Malignant Tumor of Breast|Tumors, Breast",BIOLOGICAL: BC1 cell line|BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab)|BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab) expansion cohort,BriaCell Therapeutics Corporation,,INTERVENTIONAL,2025-10-30
NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,https://clinicaltrials.gov/study/NCT02334735,COMPLETED,Melanoma,BIOLOGICAL: DC Vaccine|BIOLOGICAL: Montanide Vaccine|BIOLOGICAL: Poly-ICLC,Nina Bhardwaj,"NYU Langone Health|Memorial Sloan Kettering Cancer Center|Ludwig Institute for Cancer Research|Melanoma Research Alliance|Oncovir, Inc.",INTERVENTIONAL,2020-07-15
NCT04342962,Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT04342962,RECRUITING,Acute Myeloid Leukemia,DRUG: tagraxofusp,Gruppo Italiano Malattie EMatologiche dell'Adulto,,INTERVENTIONAL,2025-04
NCT04590261,Myeloid Cells in Patients With Covid-19 Pneumonia,https://clinicaltrials.gov/study/NCT04590261,NOT_YET_RECRUITING,Covid-19; SARS-Cov2,OTHER: Blood sampling|OTHER: Nasal Brushing,Assistance Publique - Hôpitaux de Paris,"Institut National de la Santé Et de la Recherche Médicale, France",INTERVENTIONAL,2025-12
NCT00065442,Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy,https://clinicaltrials.gov/study/NCT00065442,COMPLETED,Prostate Cancer,BIOLOGICAL: Sipuleucel-T|BIOLOGICAL: APC-Placebo,Dendreon,,INTERVENTIONAL,2009-01
NCT02496273,Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer,https://clinicaltrials.gov/study/NCT02496273,ACTIVE_NOT_RECRUITING,Gastric Cancer,BIOLOGICAL: CTL,The First People's Hospital of Changzhou,,INTERVENTIONAL,2030-12
NCT06639074,"Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial",https://clinicaltrials.gov/study/NCT06639074,NOT_YET_RECRUITING,Advanced Fallopian Tube Carcinoma|Advanced Fallopian Tube High Grade Serous Adenocarcinoma|Advanced Ovarian Carcinoma|Advanced Ovarian Carcinosarcoma|Advanced Ovarian Clear Cell Adenocarcinoma|Advanced Ovarian Endometrioid Adenocarcinoma|Advanced Ovarian High Grade Serous Adenocarcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Primary Peritoneal High Grade Serous Adenocarcinoma|Fallopian Tube Carcinosarcoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|FIGO Stage III Ovarian Cancer 2014|FIGO Stage IV Ovarian Cancer 2014|Ovarian Mixed Cell Adenocarcinoma|Primary Peritoneal Carcinosarcoma|Primary Peritoneal Clear Cell Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|DRUG: Placebo Administration|BIOLOGICAL: Tetanus and Diphtheria Toxoids Adsorbed,Mayo Clinic,,INTERVENTIONAL,2027-12-31
NCT02432846,Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC),https://clinicaltrials.gov/study/NCT02432846,COMPLETED,"Renal Cell Carcinoma, Metastatic",BIOLOGICAL: Intuvax (INN: ilixadencel)|DRUG: Sunitinib,Mendus,TFS Trial Form Support|Accelovance,INTERVENTIONAL,2021-01-31
NCT01823978,Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer,https://clinicaltrials.gov/study/NCT01823978,COMPLETED,Castrate Resistent Prostate Cancer,BIOLOGICAL: BPX-201 vaccine plus AP1903,Bellicum Pharmaceuticals,,INTERVENTIONAL,2017-09
NCT00075335,AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation,https://clinicaltrials.gov/study/NCT00075335,COMPLETED,Healthy,DRUG: AMD3100 (Mozobil plerixafor),"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL,2012-08
NCT01973322,"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized ""Proof-of-principle"" Phase II Study",https://clinicaltrials.gov/study/NCT01973322,ACTIVE_NOT_RECRUITING,Malignant Melanoma of Skin Stage III|Malignant Melanoma of Skin Stage IV,OTHER: arm 1: DC Vaccine + RT|OTHER: arm 2: DC Vaccine + IFN-alfa|OTHER: arm 3: both arm 1 and 2 + RT|BIOLOGICAL: arm 4: DC Vaccine,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,INTERVENTIONAL,2024-09-30
NCT02159950,Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT02159950,COMPLETED,Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Sipuleucel-T|DRUG: Tasquinimod,Roswell Park Cancer Institute,Active Biotech AB,INTERVENTIONAL,
NCT00454051,"Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma",https://clinicaltrials.gov/study/NCT00454051,COMPLETED,Asthma,DRUG: Omalizumab|DRUG: placebo,Novartis Pharmaceuticals,,INTERVENTIONAL,2008-03
NCT00003977,Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer,https://clinicaltrials.gov/study/NCT00003977,COMPLETED,Cervical Cancer,BIOLOGICAL: human papillomavirus 16 E7 peptide|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation,"Steward St. Elizabeth's Medical Center of Boston, Inc.",National Cancer Institute (NCI),INTERVENTIONAL,
NCT04373031,"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer",https://clinicaltrials.gov/study/NCT04373031,ACTIVE_NOT_RECRUITING,Breast Cancer|Breast Neoplasms,DRUG: Pembrolizumab|DRUG: IRX 2,Providence Health & Services,"Merck Sharp & Dohme LLC|Brooklyn ImmunoTherapeutics, LLC",INTERVENTIONAL,2025-06
NCT00626860,The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma,https://clinicaltrials.gov/study/NCT00626860,COMPLETED,Metastatic Melanoma,BIOLOGICAL: DC/tumor fusion vaccine,Beth Israel Deaconess Medical Center,"Genzyme, a Sanofi Company",INTERVENTIONAL,2008-09-10
NCT02252055,The ONE Study ATDC Trial,https://clinicaltrials.gov/study/NCT02252055,COMPLETED,"Renal Failure, End Stage",BIOLOGICAL: ATDC_Nantes,Nantes University Hospital,,INTERVENTIONAL,2018-11-14
NCT04999943,Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT04999943,RECRUITING,Myelodysplastic Syndromes|Dendritic Cell|Hypomethylating Agents|Immunotherapy,BIOLOGICAL: DC vaccine,Affiliated Hospital to Academy of Military Medical Sciences,,INTERVENTIONAL,2026-07-01
NCT05714306,PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma,https://clinicaltrials.gov/study/NCT05714306,NOT_YET_RECRUITING,Ovarian Carcinoma,BIOLOGICAL: PEP-DC1|BIOLOGICAL: OC-DC|BIOLOGICAL: PEP-DC2|DRUG: Low dose cyclophosphamide,Centre Hospitalier Universitaire Vaudois,,INTERVENTIONAL,2030-03
NCT03615404,"Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma",https://clinicaltrials.gov/study/NCT03615404,COMPLETED,"Glioblastoma|Malignant Glioma|Medulloblastoma Recurrent|Pediatric Glioblastoma Multiforme|Pediatric Brain Tumor, Recurrent|Pediatric Brain Tumor",BIOLOGICAL: CMV-DCs with GM-CSF|BIOLOGICAL: Td (tetanus toxoid),Gary Archer Ph.D.,,INTERVENTIONAL,2020-07-02
NCT00625755,A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00625755,COMPLETED,Renal Cell Carcinoma,BIOLOGICAL: Electrofusion DC vaccine,Beth Israel Deaconess Medical Center,"Genzyme, a Sanofi Company",INTERVENTIONAL,2008-02
NCT00849290,Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442),https://clinicaltrials.gov/study/NCT00849290,COMPLETED,Metastatic Androgen Independent Prostate Cancer,BIOLOGICAL: APC8015F,Dendreon,,INTERVENTIONAL,2009-04
NCT00022334,Vaccine Therapy in Treating Patients With Liver Cancer,https://clinicaltrials.gov/study/NCT00022334,COMPLETED,Liver Cancer,BIOLOGICAL: AFP,Jonsson Comprehensive Cancer Center,National Institutes of Health (NIH),INTERVENTIONAL,2008-10
NCT05246228,Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy,https://clinicaltrials.gov/study/NCT05246228,NOT_YET_RECRUITING,Squamous Cell Carcinoma of the Skin,OTHER: Peripheral blood sampling in order to evaluate changes in the circulating immune population,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Azienda Ospedaliera di Padova|Istituti Ospitalieri di Cremona|IRCCS Sacro Cuore Don Calabria di Negrar|ASST Bergamo Ovest|San Gerardo Hospital|ASST Valcamonica",OBSERVATIONAL,2025-12-30
NCT03688178,DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab,https://clinicaltrials.gov/study/NCT03688178,ACTIVE_NOT_RECRUITING,Glioblastoma,BIOLOGICAL: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|DRUG: Temozolomide|BIOLOGICAL: Varlilumab|BIOLOGICAL: Td|BIOLOGICAL: Unpulsed DCs,"Annick Desjardins, MD",Celldex Therapeutics,INTERVENTIONAL,2025-03
NCT01189383,"IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma",https://clinicaltrials.gov/study/NCT01189383,COMPLETED,Malignant Melanoma Stage III|Malignant Melanoma Stage IV,BIOLOGICAL: IL15-DC Vaccine,Baylor Research Institute,National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL,2016-12
NCT00896662,Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202,https://clinicaltrials.gov/study/NCT00896662,COMPLETED,Lymphoma|Solid Tumor,OTHER: immunologic technique|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL,2008-08
NCT03252938,Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors,https://clinicaltrials.gov/study/NCT03252938,RECRUITING,Solid Tumors|Peritoneal Carcinomatosis,DRUG: IMP321|DRUG: Avelumab,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,,INTERVENTIONAL,2025-09-30
NCT01926639,Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma,https://clinicaltrials.gov/study/NCT01926639,COMPLETED,Follicular Lymphoma,"BIOLOGICAL: Radiotherapy, rituximab and DC",Oslo University Hospital,Norwegian Cancer Society|Helse Sor-Ost,INTERVENTIONAL,2014-10
NCT00027599,APC8015 and Bevacizumab in Treating Patients With Prostate Cancer,https://clinicaltrials.gov/study/NCT00027599,COMPLETED,Prostate Cancer,BIOLOGICAL: bevacizumab|BIOLOGICAL: prostatic acid phosphatase-sargramostim fusion protein|BIOLOGICAL: sipuleucel-T|BIOLOGICAL: therapeutic autologous dendritic cells|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation,National Cancer Institute (NCI),,INTERVENTIONAL,
NCT00019084,Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00019084,COMPLETED,Breast Cancer|Cervical Cancer|Colorectal Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer,BIOLOGICAL: aldesleukin|BIOLOGICAL: mutant p53 peptide pulsed dendritic cell vaccine|BIOLOGICAL: ras peptide cancer vaccine|BIOLOGICAL: sargramostim|BIOLOGICAL: therapeutic autologous lymphocytes|BIOLOGICAL: therapeutic tumor infiltrating lymphocytes,National Cancer Institute (NCI),,INTERVENTIONAL,2003-05
NCT01851733,MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme,https://clinicaltrials.gov/study/NCT01851733,COMPLETED,Glioblastoma,DEVICE: MRI-guided Laser Heat Ablation (MLA)|DRUG: Doxorubicin|OTHER: Blood draw - dendritic cells|DEVICE: Dynamic Susceptibility Contrast Magnetic Resonance Imaging,Washington University School of Medicine,The Foundation for Barnes-Jewish Hospital,INTERVENTIONAL,2018-05-30
NCT01132014,Autologous OC-DC Vaccine in Ovarian Cancer,https://clinicaltrials.gov/study/NCT01132014,COMPLETED,Chemotherapy|Tumor|Ovarian Cancer,BIOLOGICAL: OCDC,Abramson Cancer Center at Penn Medicine,,INTERVENTIONAL,2018-05-30
NCT06530082,A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT06530082,NOT_YET_RECRUITING,Breast Neoplasms,BIOLOGICAL: CircFam53B-219aa DC vaccine|DRUG: camrelizumab,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,INTERVENTIONAL,2027-01-01
NCT02366728,DC Migration Study for Newly-Diagnosed GBM,https://clinicaltrials.gov/study/NCT02366728,COMPLETED,"Glioblastoma|Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme",BIOLOGICAL: Unpulsed DCs|BIOLOGICAL: Td|BIOLOGICAL: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|BIOLOGICAL: 111In-labeled DCs|DRUG: Temozolomide|DRUG: Saline|DRUG: Basiliximab,"Mustafa Khasraw, MBChB, MD, FRCP, FRACP",,INTERVENTIONAL,2020-10-31
NCT00082329,G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers,https://clinicaltrials.gov/study/NCT00082329,COMPLETED,Healthy,DRUG: AMD 3100 (Mozobil plerixafor)|DRUG: Granulocyte colony-stimulating factor (G-CSF),"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL,2012-10-25
NCT05344209,Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT05344209,RECRUITING,"Oncology|NSCLC Stage IV|NSCLC, Stage III",BIOLOGICAL: UV1|DRUG: Sagramostim|DRUG: Anti-PD-1/PD-L1 treatment,Vestre Viken Hospital Trust,"University Hospital, Akershus|Oslo University Hospital|Haukeland University Hospital|Helse Stavanger HF|Helse Fonna|Helse Nord-Trøndelag HF|St. Olavs Hospital|Alesund Hospital|Helse Forde|University Hospital of North Norway",INTERVENTIONAL,2027-07-01
NCT01339663,Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01339663,COMPLETED,Recurrent Melanoma|Stage IV Melanoma,DRUG: cyclophosphamide|BIOLOGICAL: aldesleukin|BIOLOGICAL: autologous tumor cell vaccine|OTHER: laboratory biomarker analysis|OTHER: immunologic technique|OTHER: immunohistochemistry staining method|GENETIC: polymerase chain reaction|BIOLOGICAL: therapeutic autologous lymphocytes,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,
NCT00901342,Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer,https://clinicaltrials.gov/study/NCT00901342,COMPLETED,Prostate Cancer,BIOLOGICAL: sipuleucel-T,Dendreon,,INTERVENTIONAL,2015-06
NCT03707808,"Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab",https://clinicaltrials.gov/study/NCT03707808,COMPLETED,Solid Tumor|Metastases to Soft Tissue,DRUG: intratumoral injection of autologous CD1c (BDCA-1)+ myDC,Universitair Ziekenhuis Brussel,,INTERVENTIONAL,2020-12-24
NCT03113643,"SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",https://clinicaltrials.gov/study/NCT03113643,RECRUITING,Acute Myeloid Leukemia|Myelodysplastic Syndrome|Blastic Plasmacytoid Dendritic Cell Neoplasm,DRUG: Azacitidine|DRUG: SL-401|DRUG: Venetoclax,Dana-Farber Cancer Institute,"Stemline Therapeutics, Inc.",INTERVENTIONAL,2026-05-31
NCT03599960,Combination Chemotherapy in Patients With Newly Diagnosed BPDCN,https://clinicaltrials.gov/study/NCT03599960,ACTIVE_NOT_RECRUITING,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),DRUG: Chemotherapy,Centre Hospitalier Universitaire de Besancon,"UMR1098, EFS BFC, BESANCON|Centre Henri Becquerel|Maisonneuve-Rosemont Hospital|Centre Hospitalier Universitaire Dijon|Inserm CIC1431, CHU Besancon",INTERVENTIONAL,2024-11
NCT01883297,"""Re-Stimulated"" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",https://clinicaltrials.gov/study/NCT01883297,ACTIVE_NOT_RECRUITING,Recurrent|Platinum-resistant|High Grade Serous Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,BIOLOGICAL: Re-stimulated tumor-infiltrating lymphocytes (TILs)|BIOLOGICAL: Interleukin-2|DRUG: Cyclophosphamide,"University Health Network, Toronto",,INTERVENTIONAL,2026-06
NCT00057915,Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer,https://clinicaltrials.gov/study/NCT00057915,COMPLETED,"Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: CEA peptide 1-6D,Duke University,National Cancer Institute (NCI),INTERVENTIONAL,2006-09
NCT00616720,Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma,https://clinicaltrials.gov/study/NCT00616720,COMPLETED,Multiple Myeloma and Plasma Cell Neoplasm,BIOLOGICAL: aldesleukin|BIOLOGICAL: idiotype-pulsed autologous dendritic cell vaccine APC8020|BIOLOGICAL: recombinant interferon gamma|GENETIC: polymerase chain reaction|GENETIC: reverse transcriptase-polymerase chain reaction|OTHER: flow cytometry|OTHER: laboratory biomarker analysis,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,2007-11
NCT01068509,Ovarian Cancer Vaccine for Patients in Remission,https://clinicaltrials.gov/study/NCT01068509,COMPLETED,Epithelial Ovarian Cancer,BIOLOGICAL: Cvac,Prima BioMed Ltd,,INTERVENTIONAL,2015-04
NCT03086564,A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT),https://clinicaltrials.gov/study/NCT03086564,COMPLETED,Hepatocellular Carcinoma,BIOLOGICAL: ADCC & TACE|PROCEDURE: TACE,Yuehua Huang,,INTERVENTIONAL,2020-10-29
NCT00601796,"Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer",https://clinicaltrials.gov/study/NCT00601796,COMPLETED,Lung Cancer,BIOLOGICAL: Vaccine Treatment|DRUG: Cyclophosphamide|DRUG: All-trans retinoic acid (ATRA),H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI)|National Institutes of Health (NIH),INTERVENTIONAL,2012-06
NCT00003229,Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal,https://clinicaltrials.gov/study/NCT00003229,COMPLETED,Melanoma (Skin),BIOLOGICAL: aldesleukin|BIOLOGICAL: gp100 antigen|BIOLOGICAL: tyrosinase peptide,Duke University,National Cancer Institute (NCI),INTERVENTIONAL,2005-02
NCT00005947,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,https://clinicaltrials.gov/study/NCT00005947,COMPLETED,Prostate Cancer,BIOLOGICAL: sipuleucel-T|BIOLOGICAL: Placebo,Dendreon,,INTERVENTIONAL,2004-09
NCT03657966,DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer,https://clinicaltrials.gov/study/NCT03657966,COMPLETED,Ovarian Cancer Recurrent,BIOLOGICAL: DCVAC/OvCa|DRUG: Standard of Care Chemotherapy,SOTIO a.s.,,INTERVENTIONAL,2021-02-25
NCT05882305,KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial,https://clinicaltrials.gov/study/NCT05882305,ACTIVE_NOT_RECRUITING,EBV-associated Lymphomas,BIOLOGICAL: Autologous monocyte-derived DCs pulsed withEBV-associated antigen,"Kousai Bio Co., Ltd.",,INTERVENTIONAL,2025-12-31
NCT00019591,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT00019591,COMPLETED,Colorectal Cancer,BIOLOGICAL: aldesleukin|BIOLOGICAL: ras peptide cancer vaccine|PROCEDURE: adjuvant therapy,National Cancer Institute (NCI),,INTERVENTIONAL,2005-11
NCT03370627,Effect of Anti-CD303 Antibodies in Autoimmune Diseases,https://clinicaltrials.gov/study/NCT03370627,COMPLETED,Immune Disease,BIOLOGICAL: Monoclonal anti-cd303 antibody,"University Hospital, Lille",Laboratoire français de Fractionnement et de Biotechnologies,INTERVENTIONAL,2019-05-25
NCT02465268,Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme,https://clinicaltrials.gov/study/NCT02465268,COMPLETED,"Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|Astrocytoma, Grade IV|GBM",BIOLOGICAL: pp65-shLAMP DC with GM-CSF|BIOLOGICAL: unpulsed PBMC and saline|DRUG: Td|DRUG: Saline|BIOLOGICAL: pp65-flLAMP DC with GM-CSF,University of Florida,National Cancer Institute (NCI),INTERVENTIONAL,2023-11-30
NCT02405338,DC Vaccination for Post-remission Therapy in AML,https://clinicaltrials.gov/study/NCT02405338,COMPLETED,Acute Myeloid Leukemia,BIOLOGICAL: WT1/PRAME vaccination,Medigene AG,,INTERVENTIONAL,2019-11
NCT06508463,Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06508463,RECRUITING,"Peripheral T Cell Lymphoma|Relapsed Peripheral T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Relapsed Anaplastic Large Cell Lymphoma|Relapsed Mycosis Fungoides",PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|PROCEDURE: Single Photon Emission Computed Tomography|BIOLOGICAL: Cemiplimab|BIOLOGICAL: Ipilimumab,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,2032-04-01
NCT00822783,Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients,https://clinicaltrials.gov/study/NCT00822783,COMPLETED,Atopic Dermatitis,DRUG: Omalizumab|DRUG: Placebo,Medical University of Vienna,,INTERVENTIONAL,2003-04
NCT00003433,Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer,https://clinicaltrials.gov/study/NCT00003433,COMPLETED,Colorectal Cancer|Metastatic Cancer,BIOLOGICAL: carcinoembryonic antigen RNA-pulsed DC cancer vaccine,Duke Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL,2003-08
NCT00019214,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00019214,COMPLETED,Melanoma (Skin),BIOLOGICAL: MART-1 antigen|BIOLOGICAL: aldesleukin|BIOLOGICAL: gp100 antigen,National Cancer Institute (NCI),,INTERVENTIONAL,2006-07
NCT05834296,Study in Subjects With Mild-to-Moderate Alzheimer's Dementia,https://clinicaltrials.gov/study/NCT05834296,ACTIVE_NOT_RECRUITING,Alzheimer Disease,BIOLOGICAL: ALZN002 (autologous DCs pulsed with E22W mutant peptide).|DRUG: Placebo,"Alzamend Neuro, Inc.","bioRASI, LLC",INTERVENTIONAL,2028-03-03
NCT01133704,"Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer",https://clinicaltrials.gov/study/NCT01133704,COMPLETED,Hormone-Refractory Prostate Cancer,BIOLOGICAL: sipuleucel-T|BIOLOGICAL: APC-Placebo,Dendreon,,INTERVENTIONAL,2005-05
NCT00090896,"CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",https://clinicaltrials.gov/study/NCT00090896,COMPLETED,Melanoma (Skin),BIOLOGICAL: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody,Jonsson Comprehensive Cancer Center,Pfizer,INTERVENTIONAL,2009-10
NCT05832216,Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia,https://clinicaltrials.gov/study/NCT05832216,RECRUITING,Aplastic Anemia|Platelet Transfusion Refractoriness,DRUG: Daratumumab,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL,2026-12-31
NCT00001644,Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection,https://clinicaltrials.gov/study/NCT00001644,COMPLETED,HIV Infection,DRUG: Indinavir|DRUG: Zidovudine|DRUG: Lamivudine|DRUG: Nevirapine|PROCEDURE: Blood testing|PROCEDURE: Lymph node biospy|PROCEDURE: Leukapheresis,National Institute of Allergy and Infectious Diseases (NIAID),,INTERVENTIONAL,2010-02-17
NCT05806814,Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer,https://clinicaltrials.gov/study/NCT05806814,RECRUITING,Metastatic Castration-Resistant Prostate Cancer (mCRPC),BIOLOGICAL: Sipuleucel-T,University of Oklahoma,Dendreon,INTERVENTIONAL,2024-11
NCT04640779,"Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma",https://clinicaltrials.gov/study/NCT04640779,RECRUITING,Recurrent Histiocytic and Dendritic Cell Neoplasm|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Histiocytic and Dendritic Cell Neoplasm|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma,DRUG: Choline Salicylate|DRUG: Selinexor,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,2027-08-15
NCT00728936,"Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients",https://clinicaltrials.gov/study/NCT00728936,COMPLETED,Hepatitis C,DRUG: IMO-2125|DRUG: Saline placebo,"Idera Pharmaceuticals, Inc.",,INTERVENTIONAL,2010-05
NCT04629274,In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO,https://clinicaltrials.gov/study/NCT04629274,COMPLETED,Neuromyelitis Optica,PROCEDURE: Blood sampling,Imcyse SA,,INTERVENTIONAL,2024-06-03
NCT04084951,"Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT04084951,COMPLETED,Adult Solid Tumor,BIOLOGICAL: SQZ-PBMC-HPV|DRUG: Atezolizumab|DRUG: Ipilimumab|DRUG: Nivolumab,SQZ Biotechnologies,,INTERVENTIONAL,2023-02-09
NCT00936572,Probiotics In Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT00936572,COMPLETED,Colorectal Cancer,"PROCEDURE: Probiotics (La1, BB536)|BIOLOGICAL: probiotics (La1, BB536)|BIOLOGICAL: placebo",University of Milano Bicocca,,INTERVENTIONAL,2007-10
NCT06253494,"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer",https://clinicaltrials.gov/study/NCT06253494,RECRUITING,Endometrial Cancer|Cancer of Endometrium|Carcinoma of Endometrium|Endometrial Carcinoma,BIOLOGICAL: AdHER2DC vaccine|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: N-803|DRUG: Lenvatinib|DEVICE: PATHWAY HER2 (4B5) assay,National Cancer Institute (NCI),,INTERVENTIONAL,2028-12-31
NCT06244069,Clonal Hematopoiesis in Giant Cell Arteritis,https://clinicaltrials.gov/study/NCT06244069,NOT_YET_RECRUITING,Giant Cell Arteritis|Temporal Arteritis|Clonal Hematopoiesis of Indeterminate Potential|Horton Disease|Systemic Vasculitis Primary,DIAGNOSTIC_TEST: Temporal arterial biopsy|DIAGNOSTIC_TEST: Whole exome sequencing|DIAGNOSTIC_TEST: Single cell transcriptomics,ASST Fatebenefratelli Sacco,,OBSERVATIONAL,2031-03
NCT00026624,Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC,https://clinicaltrials.gov/study/NCT00026624,COMPLETED,HIV Infections,"BIOLOGICAL: ALVAC(2)120(B,MN)GNP (vCP1452)|DRUG: Keyhole-Limpet Hemocyanin",National Institute of Allergy and Infectious Diseases (NIAID),,INTERVENTIONAL,2006-10
NCT00460629,Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation,https://clinicaltrials.gov/study/NCT00460629,COMPLETED,Chronic Myeloid Leukemia,PROCEDURE: Application of activated donor T cells,University Hospital Carl Gustav Carus,,INTERVENTIONAL,
NCT00990938,"Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients",https://clinicaltrials.gov/study/NCT00990938,COMPLETED,"Hepatitis C, Treatment Naïve, Genotype 1 Patients",DRUG: IMO-2125|DRUG: Saline,"Idera Pharmaceuticals, Inc.",,INTERVENTIONAL,2011-01
NCT03396575,Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I),https://clinicaltrials.gov/study/NCT03396575,ACTIVE_NOT_RECRUITING,Diffuse Intrinsic Pontine Glioma (DIPG)|Brain Stem Glioma,BIOLOGICAL: TTRNA-DC vaccines with GM-CSF|BIOLOGICAL: TTRNA-xALT|DRUG: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|DRUG: Dose-Intensified TMZ|DRUG: Td vaccine|BIOLOGICAL: Autologous Hematopoietic Stem Cells (HSC),University of Florida,Accelerate Brain Cancer Cure|Lyla Nsouli Foundation,INTERVENTIONAL,2025-06
NCT02528682,MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT,https://clinicaltrials.gov/study/NCT02528682,COMPLETED,Hematological Malignancies,BIOLOGICAL: MiHA-loaded PD-L-silenced DC Vaccination,Radboud University Medical Center,ZonMw: The Netherlands Organisation for Health Research and Development|Dutch Cancer Society,INTERVENTIONAL,2021-03-31
NCT06100705,Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC,https://clinicaltrials.gov/study/NCT06100705,RECRUITING,Metastatic Castration-resistant Prostate Cancer,DRUG: Testosterone Cypionate|DRUG: Sipuleucel-T,Yale University,Dendreon,INTERVENTIONAL,2028-03
NCT00707304,Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00707304,COMPLETED,Non Small Cell Lung Cancer,DRUG: Talactoferrin|DRUG: Placebo,Agennix,,INTERVENTIONAL,2012-08
NCT02151448,αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies,https://clinicaltrials.gov/study/NCT02151448,COMPLETED,Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface|Malignant Peritoneal Mesothelioma|Peritoneal Carcinomatosis,BIOLOGICAL: DC vaccine|DRUG: Celecoxib|DRUG: Interferon Alfa-2b|BIOLOGICAL: rintatolimod,David Bartlett,National Cancer Institute (NCI),INTERVENTIONAL,2019-02-18
NCT06329908,DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs,https://clinicaltrials.gov/study/NCT06329908,RECRUITING,Lung Cancer,DRUG: LG002,Zhen-Yu Ding,,INTERVENTIONAL,2026-10-31
NCT00053131,Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00053131,COMPLETED,Leukemia,BIOLOGICAL: filgrastim|BIOLOGICAL: sargramostim|DRUG: cytarabine|DRUG: mitoxantrone hydrochloride,Roswell Park Cancer Institute,,INTERVENTIONAL,2004-02
NCT01678937,Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents,https://clinicaltrials.gov/study/NCT01678937,COMPLETED,Liver Transplant Rejection|Immunosuppression,PROCEDURE: Blood Draw - Rapamycin|PROCEDURE: Blood Draw from Control Subjects|PROCEDURE: Blood Draw - CyA|PROCEDURE: Blood Draw - Tacrolimus|PROCEDURE: Blood Draw - MMF|PROCEDURE: Blood Draw - Rapamycin,Northwestern University,Northwestern Memorial Hospital,OBSERVATIONAL,2008-09
NCT01522820,Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,https://clinicaltrials.gov/study/NCT01522820,COMPLETED,Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Estrogen Receptor Negative|Estrogen Receptor Positive|Glioblastoma|Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Metastatic Renal Cell Cancer|Recurrent Adult Brain Neoplasm|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Lung Carcinoma|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Uterine Corpus Carcinoma|Resectable Hepatocellular Carcinoma|Sarcoma|Stage IA Breast Cancer|Stage IA Ovarian Cancer|Stage IA Uterine Corpus Cancer|Stage IB Breast Cancer|Stage IB Ovarian Cancer|Stage IB Uterine Corpus Cancer|Stage IC Ovarian Cancer|Stage II Uterine Corpus Cancer|Stage IIA Breast Cancer|Stage IIA Lung Carcinoma|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Esophageal Cancer|Stage IIB Lung Carcinoma|Stage IIB Ovarian Cancer|Stage IIB Skin Melanoma|Stage IIC Ovarian Cancer|Stage IIC Skin Melanoma|Stage IIIA Breast Cancer|Stage IIIA Esophageal Cancer|Stage IIIA Lung Carcinoma|Stage IIIA Ovarian Cancer|Stage IIIA Skin Melanoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Breast Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Skin Melanoma|Stage IIIB Uterine Corpus Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Skin Melanoma|Stage IIIC Uterine Corpus Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Esophageal Cancer|Stage IV Ovarian Cancer|Stage IV Prostate Cancer|Stage IV Skin Melanoma|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer,BIOLOGICAL: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Sirolimus,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL,2016-07
NCT05631886,Combination of CAR-DC Vaccine and ICIs in Malignant Tumors,https://clinicaltrials.gov/study/NCT05631886,RECRUITING,"Solid Tumor, Adult|Lymphoma|EphA2 Overexpression|TP53 R273H|TP53 R175H|TP53 R248Q|TP53 R249S",BIOLOGICAL: TP53-EphA-2-CAR-DC|DRUG: Abraxane|DRUG: Cyclophosphamide|DRUG: anti-PD-1 antibody|DRUG: Anti-CTLA4 Monoclonal Antibody,Chinese PLA General Hospital,Zhejiang University,INTERVENTIONAL,2026-12-30
NCT05985174,Role of Neutrophil CD64 and Monocyte HLA-DR Markers in the Dignosis of Neonatal Sepsis,https://clinicaltrials.gov/study/NCT05985174,NOT_YET_RECRUITING,Neonatal Sepsis,"DIAGNOSTIC_TEST: CD64 , HLA-DR",Sohag University,,INTERVENTIONAL,2024-08-01
NCT02775292,"Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",https://clinicaltrials.gov/study/NCT02775292,COMPLETED,Adult Solid Neoplasm|Childhood Solid Neoplasm|Metastatic Neoplasm,BIOLOGICAL: Aldesleukin|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|BIOLOGICAL: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|BIOLOGICAL: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|PROCEDURE: Positron Emission Tomography,Jonsson Comprehensive Cancer Center,Stand Up To Cancer|Bristol-Myers Squibb|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Cancer Institute (NCI),INTERVENTIONAL,2019-04-08
NCT06325748,SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS,https://clinicaltrials.gov/study/NCT06325748,RECRUITING,AML/MDS|CD33 Expressing Hematological Malignancies|FLT3 Expressing Hematological Malignancies,BIOLOGICAL: SENTI-202,Senti Biosciences,,INTERVENTIONAL,2040-08
NCT05700565,Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype,https://clinicaltrials.gov/study/NCT05700565,RECRUITING,Immune-related Adverse Event,OTHER: Extracorporeal photopheresis|OTHER: Other immunosuppressive or immunomodulatory drugs,Lucie Heinzerling,,OBSERVATIONAL,2027-01-01
NCT01431391,Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer,https://clinicaltrials.gov/study/NCT01431391,COMPLETED,Prostatic Neoplasm|Prostate Cancer|Prostatic Adenocarcinoma,BIOLOGICAL: sipuleucel-T|DRUG: leuprolide acetate,Dendreon,,INTERVENTIONAL,2014-12
NCT03686683,Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer,https://clinicaltrials.gov/study/NCT03686683,COMPLETED,Adenocarcinoma of the Prostate,BIOLOGICAL: sipuleucel-T,Dendreon,PRA Health Sciences,INTERVENTIONAL,2023-03-10
NCT00715104,Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer,https://clinicaltrials.gov/study/NCT00715104,COMPLETED,Prostate Cancer,BIOLOGICAL: Sipuleucel-T with Booster|BIOLOGICAL: Sipuleucel-T without Booster,Dendreon,"University of California, San Francisco",INTERVENTIONAL,2013-12
NCT00617409,To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid,https://clinicaltrials.gov/study/NCT00617409,COMPLETED,Small Cell Lung Cancer,DRUG: Paclitaxel|BIOLOGICAL: Drug: Ad.p53-DC vaccines|DRUG: All -trans Retinoic Acid (ATRA),H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL,2019-01-31
NCT05631899,CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT05631899,RECRUITING,"Solid Tumor, Adult|EphA2 Overexpression|KRAS G12V|KRAS G12C|KRAS G12D",BIOLOGICAL: KRAS-EphA-2-CAR-DC|DRUG: Abraxane|DRUG: Cyclophosphamide|DRUG: Anti-PD-1 antibody|DRUG: Anti-CTLA4 Monoclonal Antibody,Chinese PLA General Hospital,Zhejiang University,INTERVENTIONAL,2026-12-30
NCT02129075,A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma,https://clinicaltrials.gov/study/NCT02129075,COMPLETED,Cutaneous Melanoma|Melanoma|Melanoma of Unknown Primary|Mucosal Melanoma|Ocular Melanoma|Stage IIB Cutaneous Melanoma AJCC v6 and v7|Stage IIC Cutaneous Melanoma AJCC v6 and v7|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7,BIOLOGICAL: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|DRUG: Poly ICLC|BIOLOGICAL: Recombinant Flt3 Ligand,National Cancer Institute (NCI),,INTERVENTIONAL,2018-05-18
NCT02525042,Genetic Susceptibility to Ankylosing Spondylitis (AS) by Functional Genomics Approach,https://clinicaltrials.gov/study/NCT02525042,COMPLETED,Ankylosing Spondylitis,,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL,
NCT04612530,PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT04612530,RECRUITING,Pancreatic Cancer|Metastatic Pancreatic Cancer,DEVICE: Irreversible Electroporation (IRE)|DRUG: Nivolumab|DRUG: Toll-Like Receptor 9,"Amsterdam UMC, location VUmc",,INTERVENTIONAL,2023-06-01
NCT03600350,pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer,https://clinicaltrials.gov/study/NCT03600350,ACTIVE_NOT_RECRUITING,Prostate Cancer,BIOLOGICAL: pTVG-HP|DRUG: Nivolumab|DRUG: GM-CSF,"University of Wisconsin, Madison",Bristol-Myers Squibb|Madison Vaccines Inc. (MVI)|AIQ Solutions,INTERVENTIONAL,2027-12
NCT01487863,Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT01487863,COMPLETED,Prostate Cancer Metastatic|Hormone Refractory Prostate Cancer|Castration-resistant Prostate Cancer,BIOLOGICAL: sipuleucel-T|DRUG: abiraterone acetate,Dendreon,,INTERVENTIONAL,2016-06
NCT02420873,An Open-label Phase II Study of Lorvotuzumab Mertansine,https://clinicaltrials.gov/study/NCT02420873,COMPLETED,Leukemia,DRUG: Lorvotuzumab Mertansine (IMGN901),M.D. Anderson Cancer Center,"ImmunoGen, Inc.",INTERVENTIONAL,2017-06-06
NCT03404193,Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT03404193,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Blastic Plasmacytoid Dendritic Cell Neoplasm|Chronic Myelomonocytic Leukemia|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Refractory Acute Myeloid Leukemia|Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm|Refractory Chronic Myelomonocytic Leukemia|Refractory Mixed Phenotype Acute Leukemia,DRUG: Decitabine|OTHER: Laboratory Biomarker Analysis|DRUG: Venetoclax,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,2025-12-31
NCT03017820,"VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma",https://clinicaltrials.gov/study/NCT03017820,RECRUITING,"B-Cell Non-Hodgkin Lymphoma|Histiocytic and Dendritic Cell Neoplasm|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Plasma Cell Myeloma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Acute Myeloid Leukemia|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Plasma Cell Myeloma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma",PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|PROCEDURE: Single Photon Emission Computed Tomography|BIOLOGICAL: Cemiplimab,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,2032-04-01
NCT00804999,Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure,https://clinicaltrials.gov/study/NCT00804999,COMPLETED,Normal Contact Lens Wear,DRUG: Clear Care|DRUG: ReNu|DRUG: OPTI-FREE,Christine Sindt,Alcon Research,INTERVENTIONAL,2009-03-01
NCT01007149,Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma,https://clinicaltrials.gov/study/NCT01007149,COMPLETED,Asthma,DRUG: omalizumab|DRUG: Placebo,Novartis Pharmaceuticals,,INTERVENTIONAL,2011-02
NCT05086315,"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",https://clinicaltrials.gov/study/NCT05086315,RECRUITING,Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia Refractory|Myelodysplastic Syndromes|Blastic Plasmacytoid Dendritic Cell Neoplasia,DRUG: SAR443579,Sanofi,,INTERVENTIONAL,2030-10-15
NCT02403778,Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,https://clinicaltrials.gov/study/NCT02403778,COMPLETED,Melanoma,DRUG: VESANOID|DRUG: Ipilimumab,"University of Colorado, Denver",,INTERVENTIONAL,2023-01-18
NCT06431529,A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06431529,RECRUITING,"Tumor, Solid",BIOLOGICAL: tumor neoantigen specific T cell,JIANG LONGWEI,Nanjing University,INTERVENTIONAL,2025-12-31
NCT01066390,A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma,https://clinicaltrials.gov/study/NCT01066390,COMPLETED,Melanoma,BIOLOGICAL: TriMix-DC,Bart Neyns,,INTERVENTIONAL,2014-05
NCT00815607,Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma,https://clinicaltrials.gov/study/NCT00815607,COMPLETED,Melanoma,DRUG: INXN-1001|BIOLOGICAL: INXN-3001,Alaunos Therapeutics,,INTERVENTIONAL,2013-01
NCT06081972,Towards a Food Ingredient Clinically Proven to Benefit Gut Health: Novel RG-I Variants,https://clinicaltrials.gov/study/NCT06081972,RECRUITING,Healthy,DIETARY_SUPPLEMENT: Maltodextrin|DIETARY_SUPPLEMENT: Chicory RG-I|DIETARY_SUPPLEMENT: Carrot RG-I,"Örebro University, Sweden","NutriLeads B.V. (Wageningen, The Netherlands)|ProDigest (Ghent, Belgium)|Ambiotis (Toulouse, France)",INTERVENTIONAL,2024-12-31
NCT02979873,Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy,https://clinicaltrials.gov/study/NCT02979873,RECRUITING,Severe Aplastic Anemia,DRUG: Sirolimus,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL,2030-06-30
NCT04523246,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,https://clinicaltrials.gov/study/NCT04523246,COMPLETED,Herpes Zoster|Allergy and Immunology|Corona Virus Infection,"BIOLOGICAL: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|DRUG: Normal Saline",University of Oklahoma,Oklahoma Medical Research Foundation,INTERVENTIONAL,2023-05-19
NCT01981122,A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT01981122,COMPLETED,Metastatic Prostate Cancer,BIOLOGICAL: sipuleucel-T|DRUG: enzalutamide,Dendreon,,INTERVENTIONAL,2017-06-30
NCT00844506,p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer,https://clinicaltrials.gov/study/NCT00844506,COMPLETED,Ovarian Cancer,DRUG: P53-SLP vaccine|DRUG: Cyclophosphamide,University Medical Center Groningen,ISA Pharmaceuticals B.V.|Dutch Cancer Society,INTERVENTIONAL,2009-07
NCT04915326,IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment,https://clinicaltrials.gov/study/NCT04915326,RECRUITING,Rectal Cancer Stage T1-T2|Rectal Cancer Nodal Metastasis,PROCEDURE: rectal resection,University of Padova,Associazione Italiana per la Ricerca sul Cancro|Istituto Oncologico Veneto IRCCS|Azienda ULSS 3 Serenissima|Azienda Ulss 2 Marca Trevigiana,OBSERVATIONAL,2024-12-31
NCT05185258,Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study,https://clinicaltrials.gov/study/NCT05185258,ACTIVE_NOT_RECRUITING,"Psoriasis Vulgaris|Psoriasis|Skin Diseases|Skin Diseases, Papulosquamous|Skin and Connective Tissue Diseases",DRUG: Enstilar|DRUG: Placebo-vehicle,Aarhus University Hospital,,INTERVENTIONAL,2025-11-15
NCT02143518,Safety and Immunogenicity Study of Na-GST-1 With or Without CpG,https://clinicaltrials.gov/study/NCT02143518,COMPLETED,Hookworm Infection|Hookworm Disease,BIOLOGICAL: Na-GST-1/Alhydrogel®|BIOLOGICAL: CpG 10104,Baylor College of Medicine,George Washington University,INTERVENTIONAL,2016-10
NCT03827967,Trial of PalloV-CC in Colon Cancer,https://clinicaltrials.gov/study/NCT03827967,COMPLETED,Colon Cancer,BIOLOGICAL: PalloV-CC,George E. Peoples,,INTERVENTIONAL,2023-05-20
NCT03970746,"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC",https://clinicaltrials.gov/study/NCT03970746,ACTIVE_NOT_RECRUITING,Non Small Cell Lung Cancer,BIOLOGICAL: PDC*lung01|DRUG: Keytruda Injectable Product|DRUG: Alimta Injectable Product,PDC*line Pharma SAS,,INTERVENTIONAL,2025-12
NCT00434850,Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes,https://clinicaltrials.gov/study/NCT00434850,COMPLETED,"Diabetes Mellitus, Type 1",BIOLOGICAL: Allogeneic Pancreatic Islet Cells|DRUG: Deoxyspergualin|BIOLOGICAL: Antithymocyte globulin|BIOLOGICAL: Daclizumab or basiliximab|DRUG: Sirolimus|DRUG: Tacrolimus|BIOLOGICAL: Etanercept,National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),INTERVENTIONAL,2013-11
NCT03386513,Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN,https://clinicaltrials.gov/study/NCT03386513,ACTIVE_NOT_RECRUITING,Blastic Plasmacytoid Dendritic Cell Neoplasm|Myeloproliferative Neoplasm,DRUG: IMGN632,"ImmunoGen, Inc.",,INTERVENTIONAL,2025-12-01
NCT03034304,A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03034304,RECRUITING,Advanced Solid Tumors,BIOLOGICAL: MASCT-I|DRUG: Ifosfamide|DRUG: PD1 antibody|DRUG: Adriamycin|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Carboplatin,HRYZ Biotech Co.,,INTERVENTIONAL,2023-07
NCT04895761,"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",https://clinicaltrials.gov/study/NCT04895761,ACTIVE_NOT_RECRUITING,Breast Cancer,BIOLOGICAL: DPX-Survivac|DRUG: Letrozole 2.5mg|DRUG: Cyclophosphamide 50mg|RADIATION: XRT 10Gy x2,Providence Health & Services,,INTERVENTIONAL,2026-09-01
NCT06072612,Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.,https://clinicaltrials.gov/study/NCT06072612,RECRUITING,Breast Cancer|Metastatic Breast Cancer|Breast Neoplasm|Breast Cancer Metastatic|End Stage Cancer,BIOLOGICAL: SV-BR-1-GM|DRUG: Cyclophosphamide|DRUG: Interferon infiltration of the inoculation site|DRUG: Retifanlimab|DRUG: Treatment of Physician's Choice,BriaCell Therapeutics Corporation,,INTERVENTIONAL,2025-12
NCT06418724,Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma,https://clinicaltrials.gov/study/NCT06418724,NOT_YET_RECRUITING,Locally Advanced Cutaneous Squamous Cell Carcinoma,DRUG: Cetuximab|DRUG: Cemiplimab,Melanoma and Skin Cancer Trials Limited,,INTERVENTIONAL,2028-12-01
NCT06295159,Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma,https://clinicaltrials.gov/study/NCT06295159,RECRUITING,Melanoma Stage III|Melanoma Stage IV|Advanced Melanoma|Melanoma,DRUG: Nivolumab|DRUG: Nivolumab + Relatlimab|DRUG: Ipilimumab,H. Lee Moffitt Cancer Center and Research Institute,Bristol-Myers Squibb,INTERVENTIONAL,2027-03
NCT00490529,Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL,https://clinicaltrials.gov/study/NCT00490529,COMPLETED,"Lymphoma, Mantle-Cell",BIOLOGICAL: CpG-MCL vaccine|BIOLOGICAL: PF-3512676|PROCEDURE: Vaccine-primed T-cells|PROCEDURE: Autologous hematopoietic stem cell transplant (HSCT)|DRUG: Rituximab|DRUG: Standard induction chemotherapy|DRUG: Cyclophosphamide|DRUG: Filgrastim,Ronald Levy,National Institutes of Health (NIH),INTERVENTIONAL,2017-12-14
NCT00397579,DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes,https://clinicaltrials.gov/study/NCT00397579,COMPLETED,Leukemia|Myelodysplastic Syndromes|Blastic Plasmacytoid Dendritic Cell Neoplasm,DRUG: DT388IL3,University of Texas Southwestern Medical Center,,INTERVENTIONAL,2017-07-27
NCT04969887,Combination Immunotherapy in Rare Cancers Under InvesTigation,https://clinicaltrials.gov/study/NCT04969887,ACTIVE_NOT_RECRUITING,Advanced Biliary Tract Cancer|Neuroendocrine Tumors|Female Reproductive System Neoplasm|MSI-H Solid Malignant Tumor,DRUG: Ipilimumab|DRUG: Nivolumab,Olivia Newton-John Cancer Research Institute,Bristol-Myers Squibb,INTERVENTIONAL,2028-03
NCT02923934,A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers,https://clinicaltrials.gov/study/NCT02923934,COMPLETED,Gastrointestinal Cancer|Neuroendocrine Tumours|Malignant Female Reproductive System Neoplasm,DRUG: Ipilimumab|DRUG: Nivolumab,Olivia Newton-John Cancer Research Institute,Bristol-Myers Squibb,INTERVENTIONAL,2023-12-12
NCT04989946,"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer",https://clinicaltrials.gov/study/NCT04989946,RECRUITING,Prostate Cancer,DRUG: Degarelix|BIOLOGICAL: pTVG-AR|DRUG: Nivolumab|DRUG: Cemiplimab|DRUG: Fianlimab|DRUG: FLT PET/CT,"University of Wisconsin, Madison","Madison Vaccines, Inc|United States Department of Defense|Regeneron Pharmaceuticals|Bristol-Myers Squibb|National Cancer Institute (NCI)",INTERVENTIONAL,2028-12
NCT03138161,"SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma",https://clinicaltrials.gov/study/NCT03138161,RECRUITING,Advanced Soft Tissue Sarcoma|Metastatic Soft Tissue Sarcoma,DRUG: Trabectedin|DRUG: Ipilimumab|DRUG: Nivolumab,"Sarcoma Oncology Research Center, LLC",Bristol-Myers Squibb,INTERVENTIONAL,2025-03-31
NCT03329950,A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT03329950,COMPLETED,Melanoma|Non-small Cell Lung Cancer|Breast Cancer|Gastric Cancer|Renal Cell Carcinoma|Ovarian Cancer|Cholangiocarcinoma|Bladder Urothelial Carcinoma|Pancreatic Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Hepatic Cancer|Head and Neck Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Other Solid Tumors|Diffuse Large B-cell Lymphoma (DLBCL)|Mantle Cell Lymphoma|Indolent B-cell Lymphomas|Non-Hodgkin Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Waldenstrom's Disease|Marginal Zone Lymphoma|Mucosa Associated Lymphoid Tissue|Small Lymphocytic Leukemia,DRUG: CDX-1140|DRUG: CDX-301|DRUG: pembrolizumab|DRUG: Chemotherapy,Celldex Therapeutics,Merck Sharp & Dohme LLC,INTERVENTIONAL,2022-09-13
NCT02194439,Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease,https://clinicaltrials.gov/study/NCT02194439,COMPLETED,Graft-Versus-Host Disease,,Indiana University,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),OBSERVATIONAL,2019-09-30
